CN101085081A - Composition containing fructus aurantii for treating cardiovascular diseases and its preparation - Google Patents
Composition containing fructus aurantii for treating cardiovascular diseases and its preparation Download PDFInfo
- Publication number
- CN101085081A CN101085081A CN 200610014202 CN200610014202A CN101085081A CN 101085081 A CN101085081 A CN 101085081A CN 200610014202 CN200610014202 CN 200610014202 CN 200610014202 A CN200610014202 A CN 200610014202A CN 101085081 A CN101085081 A CN 101085081A
- Authority
- CN
- China
- Prior art keywords
- ultrafiltration
- radix
- adjuvant
- alcohol
- fructus aurantii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 46
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 208000024172 Cardiovascular disease Diseases 0.000 title abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 122
- 239000006187 pill Substances 0.000 claims abstract description 107
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 78
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 78
- 239000000758 substrate Substances 0.000 claims abstract description 38
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 26
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 26
- 235000008434 ginseng Nutrition 0.000 claims abstract description 26
- 235000015511 Liquidambar orientalis Nutrition 0.000 claims abstract description 19
- 206010002383 Angina Pectoris Diseases 0.000 claims abstract description 4
- 241000208340 Araliaceae Species 0.000 claims abstract 3
- 238000000108 ultra-filtration Methods 0.000 claims description 226
- 239000007788 liquid Substances 0.000 claims description 158
- 239000002671 adjuvant Substances 0.000 claims description 130
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 101
- -1 polyoxyethylene monostearate Polymers 0.000 claims description 81
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 77
- 239000003921 oil Substances 0.000 claims description 64
- 229940079593 drug Drugs 0.000 claims description 47
- 238000000034 method Methods 0.000 claims description 43
- 239000012528 membrane Substances 0.000 claims description 42
- 229930006000 Sucrose Natural products 0.000 claims description 39
- 239000005720 sucrose Substances 0.000 claims description 39
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 33
- 239000000243 solution Substances 0.000 claims description 32
- 239000000284 extract Substances 0.000 claims description 31
- 239000008101 lactose Substances 0.000 claims description 31
- 230000000737 periodic effect Effects 0.000 claims description 29
- 235000015073 liquid stocks Nutrition 0.000 claims description 26
- 239000011550 stock solution Substances 0.000 claims description 26
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims description 24
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 23
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 22
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 21
- 239000000811 xylitol Substances 0.000 claims description 21
- 235000010447 xylitol Nutrition 0.000 claims description 21
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 21
- 229960002675 xylitol Drugs 0.000 claims description 21
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 20
- 229920002472 Starch Polymers 0.000 claims description 19
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 19
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 19
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 19
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 19
- 239000008107 starch Substances 0.000 claims description 19
- 235000019698 starch Nutrition 0.000 claims description 19
- 239000004870 Styrax Substances 0.000 claims description 18
- 235000000126 Styrax benzoin Nutrition 0.000 claims description 18
- 229920002492 poly(sulfone) Polymers 0.000 claims description 18
- 238000004132 cross linking Methods 0.000 claims description 17
- 235000010489 acacia gum Nutrition 0.000 claims description 15
- 239000001785 acacia senegal l. willd gum Substances 0.000 claims description 15
- 244000153234 Hibiscus abelmoschus Species 0.000 claims description 14
- ALHUZKCOMYUFRB-OAHLLOKOSA-N Muscone Chemical compound C[C@@H]1CCCCCCCCCCCCC(=O)C1 ALHUZKCOMYUFRB-OAHLLOKOSA-N 0.000 claims description 14
- ALHUZKCOMYUFRB-UHFFFAOYSA-N muskone Natural products CC1CCCCCCCCCCCCC(=O)C1 ALHUZKCOMYUFRB-UHFFFAOYSA-N 0.000 claims description 14
- 241000756943 Codonopsis Species 0.000 claims description 13
- 229940075507 glyceryl monostearate Drugs 0.000 claims description 11
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 11
- 229920006393 polyether sulfone Polymers 0.000 claims description 11
- 239000000377 silicon dioxide Substances 0.000 claims description 10
- 239000009636 Huang Qi Substances 0.000 claims description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 9
- 241001597008 Nomeidae Species 0.000 claims description 9
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 8
- 235000010418 carrageenan Nutrition 0.000 claims description 8
- 229920001525 carrageenan Polymers 0.000 claims description 8
- 229920002239 polyacrylonitrile Polymers 0.000 claims description 8
- 235000012239 silicon dioxide Nutrition 0.000 claims description 8
- 150000005846 sugar alcohols Chemical class 0.000 claims description 8
- 229920001747 Cellulose diacetate Polymers 0.000 claims description 7
- 239000002033 PVDF binder Substances 0.000 claims description 7
- 229920002981 polyvinylidene fluoride Polymers 0.000 claims description 7
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 6
- 239000000679 carrageenan Substances 0.000 claims description 6
- 229940113118 carrageenan Drugs 0.000 claims description 6
- 238000000703 high-speed centrifugation Methods 0.000 claims description 6
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 claims description 6
- 229960001866 silicon dioxide Drugs 0.000 claims description 6
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 6
- 108010010803 Gelatin Proteins 0.000 claims description 5
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- 239000008273 gelatin Substances 0.000 claims description 5
- 229920000159 gelatin Polymers 0.000 claims description 5
- 229940014259 gelatin Drugs 0.000 claims description 5
- 235000019322 gelatine Nutrition 0.000 claims description 5
- 235000011852 gelatine desserts Nutrition 0.000 claims description 5
- 229910052756 noble gas Inorganic materials 0.000 claims description 5
- 229960000502 poloxamer Drugs 0.000 claims description 5
- 229920001983 poloxamer Polymers 0.000 claims description 5
- 238000001179 sorption measurement Methods 0.000 claims description 5
- 239000004202 carbamide Substances 0.000 claims description 4
- 235000013877 carbamide Nutrition 0.000 claims description 4
- 229920002678 cellulose Polymers 0.000 claims description 4
- 239000001913 cellulose Substances 0.000 claims description 4
- 235000010980 cellulose Nutrition 0.000 claims description 4
- 229920002301 cellulose acetate Polymers 0.000 claims description 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 4
- 235000013399 edible fruits Nutrition 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 239000000194 fatty acid Substances 0.000 claims description 4
- 229930195729 fatty acid Natural products 0.000 claims description 4
- 150000004665 fatty acids Chemical class 0.000 claims description 4
- 150000002191 fatty alcohols Chemical class 0.000 claims description 4
- 238000001471 micro-filtration Methods 0.000 claims description 4
- 150000002772 monosaccharides Chemical class 0.000 claims description 4
- 229920001542 oligosaccharide Polymers 0.000 claims description 4
- 150000002482 oligosaccharides Chemical class 0.000 claims description 4
- KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 claims description 4
- 229920001282 polysaccharide Polymers 0.000 claims description 4
- 239000005017 polysaccharide Substances 0.000 claims description 4
- 150000004804 polysaccharides Chemical class 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 229920001817 Agar Polymers 0.000 claims description 3
- 229920000858 Cyclodextrin Polymers 0.000 claims description 3
- 239000004375 Dextrin Substances 0.000 claims description 3
- 229920001353 Dextrin Polymers 0.000 claims description 3
- 239000004695 Polyether sulfone Substances 0.000 claims description 3
- 239000008272 agar Substances 0.000 claims description 3
- 235000010443 alginic acid Nutrition 0.000 claims description 3
- 239000000783 alginic acid Substances 0.000 claims description 3
- 229920000615 alginic acid Polymers 0.000 claims description 3
- 229960001126 alginic acid Drugs 0.000 claims description 3
- 150000004781 alginic acids Chemical class 0.000 claims description 3
- 238000005352 clarification Methods 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 3
- KXJGSNRAQWDDJT-UHFFFAOYSA-N 1-acetyl-5-bromo-2h-indol-3-one Chemical compound BrC1=CC=C2N(C(=O)C)CC(=O)C2=C1 KXJGSNRAQWDDJT-UHFFFAOYSA-N 0.000 claims description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 2
- 229920000178 Acrylic resin Polymers 0.000 claims description 2
- 239000004925 Acrylic resin Substances 0.000 claims description 2
- 229920002101 Chitin Polymers 0.000 claims description 2
- 229920002307 Dextran Polymers 0.000 claims description 2
- 244000286663 Ficus elastica Species 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- 244000275012 Sesbania cannabina Species 0.000 claims description 2
- 229920002125 Sokalan® Polymers 0.000 claims description 2
- 235000004298 Tamarindus indica Nutrition 0.000 claims description 2
- 240000004584 Tamarindus indica Species 0.000 claims description 2
- 229960001631 carbomer Drugs 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- 229920000591 gum Polymers 0.000 claims description 2
- 229920001277 pectin Polymers 0.000 claims description 2
- 239000001814 pectin Substances 0.000 claims description 2
- 235000010987 pectin Nutrition 0.000 claims description 2
- 229960000292 pectin Drugs 0.000 claims description 2
- 229920001721 polyimide Polymers 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 239000002244 precipitate Substances 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 235000002639 sodium chloride Nutrition 0.000 claims description 2
- 229920001285 xanthan gum Polymers 0.000 claims description 2
- 235000010493 xanthan gum Nutrition 0.000 claims description 2
- 239000000230 xanthan gum Substances 0.000 claims description 2
- 229940082509 xanthan gum Drugs 0.000 claims description 2
- 244000028419 Styrax benzoin Species 0.000 claims 2
- 238000011017 operating method Methods 0.000 claims 1
- 238000009423 ventilation Methods 0.000 claims 1
- 239000000463 material Substances 0.000 abstract description 40
- 241000196324 Embryophyta Species 0.000 abstract description 22
- 239000002202 Polyethylene glycol Substances 0.000 abstract description 7
- 208000029078 coronary artery disease Diseases 0.000 abstract description 7
- 229920001223 polyethylene glycol Polymers 0.000 abstract description 7
- 241000007126 Codonopsis pilosula Species 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 4
- 239000000470 constituent Substances 0.000 abstract description 3
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 abstract 1
- FACFHHMQICTXFZ-UHFFFAOYSA-N 2-(2-phenylimidazo[1,2-a]pyridin-3-yl)ethanamine Chemical compound N1=C2C=CC=CN2C(CCN)=C1C1=CC=CC=C1 FACFHHMQICTXFZ-UHFFFAOYSA-N 0.000 abstract 1
- 241000213006 Angelica dahurica Species 0.000 abstract 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 abstract 1
- 241000723346 Cinnamomum camphora Species 0.000 abstract 1
- 244000183685 Citrus aurantium Species 0.000 abstract 1
- 235000007716 Citrus aurantium Nutrition 0.000 abstract 1
- 241000402754 Erythranthe moschata Species 0.000 abstract 1
- 240000007890 Leonurus cardiaca Species 0.000 abstract 1
- 235000000802 Leonurus cardiaca ssp. villosus Nutrition 0.000 abstract 1
- 241000893513 Liquidambar orientalis Species 0.000 abstract 1
- 229940107666 astragalus root Drugs 0.000 abstract 1
- 229960000846 camphor Drugs 0.000 abstract 1
- 229930008380 camphor Natural products 0.000 abstract 1
- 239000001886 liquidambar orientalis Substances 0.000 abstract 1
- 229940067137 musk ketone Drugs 0.000 abstract 1
- 239000010669 rosewood oil Substances 0.000 abstract 1
- 210000003296 saliva Anatomy 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000001914 filtration Methods 0.000 description 77
- 239000000706 filtrate Substances 0.000 description 71
- 235000019198 oils Nutrition 0.000 description 62
- 239000004744 fabric Substances 0.000 description 49
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 48
- 230000008859 change Effects 0.000 description 27
- 239000012141 concentrate Substances 0.000 description 26
- 229940057995 liquid paraffin Drugs 0.000 description 26
- 244000131316 Panax pseudoginseng Species 0.000 description 25
- 238000005516 engineering process Methods 0.000 description 25
- 108090000862 Ion Channels Proteins 0.000 description 24
- 102000004310 Ion Channels Human genes 0.000 description 24
- 238000000605 extraction Methods 0.000 description 24
- 239000002932 luster Substances 0.000 description 24
- 239000012567 medical material Substances 0.000 description 24
- 229910052757 nitrogen Inorganic materials 0.000 description 24
- 238000010298 pulverizing process Methods 0.000 description 19
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 241000736148 Styrax Species 0.000 description 16
- 239000000126 substance Substances 0.000 description 15
- 230000006837 decompression Effects 0.000 description 14
- 238000004140 cleaning Methods 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 230000034994 death Effects 0.000 description 10
- 238000011001 backwashing Methods 0.000 description 9
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 7
- 229920000881 Modified starch Polymers 0.000 description 7
- 208000026106 cerebrovascular disease Diseases 0.000 description 7
- 230000002526 effect on cardiovascular system Effects 0.000 description 7
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000002481 ethanol extraction Methods 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 229920002545 silicone oil Polymers 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000000469 ethanolic extract Substances 0.000 description 5
- 208000010125 myocardial infarction Diseases 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 4
- PYMYPHUHKUWMLA-LMVFSUKVSA-N aldehydo-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 4
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 4
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000001212 derivatisation Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000008899 fufang danshen Substances 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 239000006225 natural substrate Substances 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- PVNIQBQSYATKKL-UHFFFAOYSA-N tripalmitin Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC PVNIQBQSYATKKL-UHFFFAOYSA-N 0.000 description 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 3
- 206010008190 Cerebrovascular accident Diseases 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 3
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 3
- 240000007164 Salvia officinalis Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000005708 Sodium hypochlorite Substances 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 238000000429 assembly Methods 0.000 description 3
- 230000000712 assembly Effects 0.000 description 3
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000011010 flushing procedure Methods 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 229920000570 polyether Polymers 0.000 description 3
- 235000005412 red sage Nutrition 0.000 description 3
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 2
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 241001061264 Astragalus Species 0.000 description 2
- 235000010110 Astragalus glycyphyllos Nutrition 0.000 description 2
- 241000218176 Corydalis Species 0.000 description 2
- HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 241000628997 Flos Species 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000233855 Orchidaceae Species 0.000 description 2
- 235000003181 Panax pseudoginseng Nutrition 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 2
- 150000005215 alkyl ethers Chemical class 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 235000006533 astragalus Nutrition 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 239000000919 ceramic Substances 0.000 description 2
- 239000002826 coolant Substances 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 239000008394 flocculating agent Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 231100001261 hazardous Toxicity 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 239000000905 isomalt Substances 0.000 description 2
- 235000010439 isomalt Nutrition 0.000 description 2
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 2
- 230000010410 reperfusion Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000007560 sedimentation technique Methods 0.000 description 2
- 239000009877 shengmai Substances 0.000 description 2
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229920002994 synthetic fiber Polymers 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229960001947 tripalmitin Drugs 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- IQXJCCZJOIKIAD-UHFFFAOYSA-N 1-(2-methoxyethoxy)hexadecane Chemical compound CCCCCCCCCCCCCCCCOCCOC IQXJCCZJOIKIAD-UHFFFAOYSA-N 0.000 description 1
- JECYNCQXXKQDJN-UHFFFAOYSA-N 2-(2-methylhexan-2-yloxymethyl)oxirane Chemical compound CCCCC(C)(C)OCC1CO1 JECYNCQXXKQDJN-UHFFFAOYSA-N 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 241000237970 Conus <genus> Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- SHWNNYZBHZIQQV-UHFFFAOYSA-J EDTA monocalcium diisodium salt Chemical compound [Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-J 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 description 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- IYNDLOXRXUOGIU-LQDWTQKMSA-M benzylpenicillin potassium Chemical compound [K+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 IYNDLOXRXUOGIU-LQDWTQKMSA-M 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 description 1
- 229950009789 cetomacrogol 1000 Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000008395 clarifying agent Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000005493 condensed matter Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000005243 fluidization Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 150000002333 glycines Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 239000001341 hydroxy propyl starch Substances 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 230000003680 myocardial damage Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940093430 polyethylene glycol 1500 Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 206010048282 zoonosis Diseases 0.000 description 1
Abstract
The invention discloses a Chinese medicinal composition for treating cardiovascular diseases, which is prepared mainly from root of red rooted saliva, notoginseng, bitter orange, Chinese angelica root, motherwort, astragalus root, ginseng or Codonopsis pilosula, any one of the compositions may also comprise baras camphor, rosewood oil, liquidambar orientalis mill, musk or musk ketone. The invention also discloses preparations using any one of the medicinal compositions as the effective constituents, preferably drop pills. The auxiliary materials of the drop pill substrate can be polyethylene glycol or natural materials, especially those of plant sources. The medicament has quick effect and good therapeutic action for coronary disease and angina pectoris.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition and preparation thereof that contains Fructus Aurantii treatment cardiovascular disease, particularly relating to a kind of is the pharmaceutical composition of the treatment cardiovascular disease made of raw material with the Chinese medicine medical material.
Background technology
According to China's Epidemiological study, though over nearly 50 years in the rural area or the city, the M ﹠ M of cardiovascular and cerebrovascular disease is all in rising trend.50-60 age China population cause of death central vessel disease and cerebrovascular occupy the five or six respectively, then rise to the two or three respectively later in 1970, and cardiovascular and cerebrovascular disease death person has accounted for first of whole disease cause of the death.China accounts for part proportioning of total dead population because of cardiovascular and cerebrovascular disease death person, rise to 42.6% of calendar year 2001 by 12.07% of nineteen fifty-seven, the person reaches 2,000,000 to die from the cardiovascular and cerebrovascular disease every year, though other has the part patient to survive through rescue, but majority stays deformity, can't take care of oneself, cause serious burden to relatives and society.Cardiovascular and cerebrovascular disease also is western countries crowd main causes of death.Infer that according to present existing epidemiologic data advancing of disease trend is: to the year two thousand twenty, the human diseases cause of the death puts in order will have great change, but coronary heart disease and apoplexy will be first and second of the human cause of the death.Till that time, estimate that global coronary heart disease death number will increase to 1,100 ten thousand from 6,300,000 of nineteen ninety; Apoplexy increases to 7,700,000 from 4,400,000.Blood circulation cause of the death formation will increase 59.6% in 30 years, and coronary heart disease and apoplexy increase 74.6% and 75% respectively.These data prove absolutely that cardiovascular and cerebrovascular disease is not only the principal disease of harm humans health, especially human " the No.1 killer " who causes death, disables at present and in following 20 years.
In the medicine of cardiovascular and cerebrovascular disease, the application of Chinese medicine and western medicine emphasizes particularly on different fields, and Chinese medicine also occupies the bigger market share with the little advantage of its side effect.For example: the benefiting QI for activating blood circulation side [Zhu Weifeng, Shandong College of Traditional Chinese Medicine's journal, 1994,18 (5)] that forms by Radix Ginseng, Radix Codonopsis, Radix Angelicae Sinensis, Radix Salviae Miltiorrhizae, Flos Carthami; Add the red stilbene SHENGMAI YIN that Radix Salviae Miltiorrhizae, Radix Ginseng, Radix Notoginseng, Flos Carthami, Rhizoma Corydalis, Fructus Crataegi are formed, [Chen Yuchun, the bright traditional Chinese medical science, 1999,14 (5)] by SHENGMAI YIN; The coronary heart disease of being made up of Radix Ginseng, Radix Codonopsis, Radix Ophiopogonis, Radix Salviae Miltiorrhizae, Rhizoma Chuanxiong, Lignum Dalbergiae Odoriferae is square [Wang Jinrong etc., Liaoning Journal of Traditional Chinese Medicine, 2001,28 (8)] substantially; By Radix Salviae Miltiorrhizae, Rhizoma Corydalis, Radix Ginseng, Radix Notoginseng, Rhizoma Chuanxiong, when the Shuxintongmai sheet that is grouped into [Wang Xiue etc., Shandong journal of Chinese medicine, 1997,16 (8)]; Or the like.But above clinical prescription and Chinese patent medicine all have certain weak point, or are partial to QI invigorating, or relatively activate yang, or relatively invigorate blood circulation, and do not obtain clinically popularizing in an all-round way.And dosage form mostly is traditional conventional tablet, capsule etc., production technology is more backward, and active constituent content is low, no quality control standard, therefore, utilize the new treatment cardiovascular disease of new technology development particularly the Chinese medicine of coronary heart disease be the target that vast medical worker makes great efforts.
Membrane separation technique (Membrane Separation Technique) is an emerging high efficient separation technology, by internationally recognized be a most rising great high production tech of mid-term 20 end of the centurys to 21 century.Ultrafiltration (Ultrafiltration, UF) technology is a kind of membrane separation technique, its ultimate principle is to utilize fenestra selectivity sieve performance, with separation, purification and condensed matter.Hyperfiltration process is that the anisotropic membrane (being asymmetric membrane) that utilizes macromolecular material to make is a filter medium, under normal temperature condition, relies on certain pressure and flow velocity, makes flow of solution through face, forces low molecular weight substance to see through film, and polymer substance is trapped.
The relevant practical application that utilizes ultrafiltration preparation to contain red sage formulation, the rare report of present document, particularly, utilize ultrafiltration to carry out suitability for industrialized production is a technical barrier in this area always.The inventor is through the effort of long-term and unremitting ground, by a large amount of experimental datas are analyzed, verified that ultrafiltration prepares the feasibility of compound red sage root preparation, and determined suitable process condition, for the suitability for industrialized production of utilizing ultrafiltration to carry out compound red sage root preparation provides concrete solution.
Drop pill then has the characteristics of quick acting, relatively is fit to the need of the first aid of coronary disease with angina pectoris.Although drop pill had had very big development on production equipment, preparation technology and types of drugs in recent years, go up slower development for the research and the application of drop pill new medium adjuvant.So far, most of drop pill substrate is selected Polyethylene Glycol for use, selects polyoxyethylene monostearate, gelatin, poloxamer, polyethers etc. individually for use.From the source, Polyethylene Glycol, polyoxyethylene monostearate, poloxamer, polyethers etc. all adopt making of synthetic, though gelatin from natural, it mainly comes from skin and the bone of animal.From safety perspective,, hemolytic is in various degree arranged all though that these chemical synthetic materials such as Polyethylene Glycol, polyoxyethylene monostearate, poloxamer, polyethers all can be done is medicinal; And in the chemosynthesis process, can mix unavoidably some to the chemical constituent of human body toxic side effect as oxirane, expoxy propane etc.; In addition, these synthetic materials and many medicines have incompatibility, as salicylic acid, diphenhydramine, potassium penicillin G, tetracycline etc., thereby have reduced the curative effect of these medicines.With regard to gelatin, the supplementary material of present many animal origins is carried out forbidding for avoiding zoonosis such as bovine spongiform encephalopathy, foot and mouth disease etc., and its purposes is limited.Therefore, in order to improve the product quality of drop pill, widen the application of drop pill in medical product, promote the development of drop pill dosage form, promote the internationalization of drop pill product, the drop pill new medium adjuvant of research, exploitation safety non-toxic has profound significance.But, because dropping pill formulation technology is very strict for the requirement of substrate adjuvant, often be difficult to prepare the drop pill that conforms to quality requirements after changing the substrate adjuvant, therefore, seek suitable substrate adjuvant and replace the direction that current Polyethylene Glycol becomes medical personnel effort always.
Summary of the invention
One of purpose of the present invention is to overcome the deficiencies in the prior art, and a kind of compositions for the treatment of cardiovascular disease is provided.
It is the preparation of effective ingredient that another object of the present invention provides with the said composition.
The present invention is implemented by the following technical programs:
Compositions of the present invention is mainly made by following raw materials in weight portion medicine: Radix Salviae Miltiorrhizae 20～97, Radix Notoginseng 2～79, Fructus Aurantii 3～35; Also can add Radix Angelicae Sinensis or Herba Leonuri in the crude drug, its weight portion proportioning is a Radix Salviae Miltiorrhizae 20～97, Radix Notoginseng 2～79, Fructus Aurantii 3～35, Radix Angelicae Sinensis or Herba Leonuri 5～25; Perhaps add the Radix Astragali or Radix Ginseng or Radix Codonopsis, its weight portion proportioning is a Radix Salviae Miltiorrhizae 20～97, Radix Notoginseng 2～79, Fructus Aurantii 3～35, the Radix Astragali or Radix Ginseng or Radix Codonopsis 10～40; Further, in above-mentioned arbitrary prescription, also can add Borneolum Syntheticum or Lignum Dalbergiae Odoriferae oil or Styrax or Moschus or muscone in the crude drug, its weight portion proportioning is a Radix Salviae Miltiorrhizae 20～97, Radix Notoginseng 2～79, Fructus Aurantii 3～35, Borneolum Syntheticum or Lignum Dalbergiae Odoriferae oil or Styrax or Moschus or muscone 0.2～3; Radix Salviae Miltiorrhizae 20～97, Radix Notoginseng 2～79, Fructus Aurantii 3～35, Radix Angelicae Sinensis or Herba Leonuri 5～25, Borneolum Syntheticum or Lignum Dalbergiae Odoriferae oil or Styrax or Moschus or muscone 0.2～3; Radix Salviae Miltiorrhizae 20～97, Radix Notoginseng 2～79, Fructus Aurantii 3～35, the Radix Astragali or Radix Ginseng or Radix Codonopsis 10～40, Borneolum Syntheticum or Lignum Dalbergiae Odoriferae oil or Styrax or Moschus or muscone 0.2～3.
But above-mentioned raw materials medicine both medication powder directly is mixed with compositions, also can will make preparation again behind whole crude drug or the part material medicine extraction extractum.Available decoction and alcohol sedimentation technique obtains extractum; Also available alcohol or water alcohol extracting method obtain extractum, and wherein alcohol is lower alcohol such as methanol, ethanol, normal propyl alcohol, isopropyl alcohol, n-butyl alcohol, isobutanol etc.; Further coarse filtration, ultrafiltration of the extracting solution that decoction and alcohol sedimentation technique or alcohol extracting method or water alcohol extracting method obtain, the ultrafiltrate reconcentration becomes extractum.The preferred for preparation method may further comprise the steps:
(a) with Radix Salviae Miltiorrhizae, Radix Notoginseng, Fructus Aurantii, perhaps Radix Salviae Miltiorrhizae, Radix Notoginseng, Fructus Aurantii, Radix Angelicae Sinensis or Herba Leonuri, perhaps Radix Salviae Miltiorrhizae, Radix Notoginseng, Fructus Aurantii, the Radix Astragali or Radix Ginseng or Radix Codonopsis are separately or be mixed and made into water extract or alcohol extract;
(b) described extracting solution being carried out predefecation handles;
(c) further described extracting solution is carried out hyperfiltration treatment;
(d) ultrafiltrate is condensed into extractum, or adds Borneolum Syntheticum or Lignum Dalbergiae Odoriferae oil or Styrax or Moschus or muscone again, promptly.
Wherein in the step (a), alcohol extract can be the extracting solution of the lower alcohol of variable concentrations such as methanol, ethanol, normal propyl alcohol, isopropyl alcohol, n-butyl alcohol, isobutanol etc. or the extracting solution of its mixture.Carrying out next step predefecation after alcohol extract can not concentrate or suitably concentrate handles.
In the step (b), preliminary clarifying treatment can be carried out coarse filtration with general material such as gauze, tiffany etc., the also available material such as the ceramic membrane of specialty carry out microfiltration, also can behind high speed centrifugation, divide and get supernatant, adsorption clarifications such as also available flocculating agent such as flocculate with chitosan clarifier, 101 fruit juice clarifiers, ZTC1+1 natural clarifying agent, Ovum Gallus domesticus album flocculating agent and remove particle bigger in the medicinal liquid, also available alcohol deposition method is removed most impurity.Both can singly use above-mentioned defecation method, but also use in conjunction, coarse filtration-adsorption clarification for example, adsorption clarification-high speed centrifugation, coarse filtration-microfiltration, coarse filtration-precipitate with ethanol etc.After can not concentrating or suitably concentrate, the solution that predefecation is handled carries out next step ultrafiltration; Preferably do not concentrate the ultrafiltration of promptly carrying out next step.
In the step (c), the used ultrafilter membrane of ultrafiltration can be cellulose diacetate film (CA), three cellulose acetate membrane (CTA), cyanoethyl cellulose film (CN-CA), polysulfone membrane (PS), sulfonated polysulfone membrane (SPS), poly (ether sulfone) film (PES), sulfonated polyether sulfone film (SPES), polysulfonamides film (PSA), phenolphthalein side group polyarylsulfone (PAS) film (PDS), polyvinylidene fluoride film (PVDF), polyacrylonitrile film (PAN), polyimide film (N), cellulose membrane, methyl methacrylate-acrylonitrile copolymer film (MMA-AN), polyacrylonitrile/cellulose diacetate (PAN/CA) blend film, the dynamically ultrafilter membrane that forms, and the Modified Membrane of above-mentioned film.Be preferably cellulose diacetate film (CA), three cellulose acetate membrane (CTA), polysulfone membrane (PS), sulfonated polysulfone membrane (SPS), poly (ether sulfone) film (PES), sulfonated polyether sulfone film (SPES), polysulfonamides film (PSA), polyvinylidene fluoride film (PVDF), polyacrylonitrile film (PAN).
The molecular cut off of above-mentioned ultrafilter membrane is generally 6000～80000, is preferably 10000～70000, and the best is 20000～50000.
Ultrafiltration both can be adopted cross flow filter, also can adopt dead-end filtration, but preferred cross flow filter.
The operating condition of ultrafiltration technology is as follows:
(1) the inlet pressure of ultrafiltration is 0.1～0.5MPa, is preferably 0.1～0.35Mpa, and the best is 0.25～0.35Mpa; The liquid outlet pressure ratio inlet pressure of ultrafiltration hangs down 0.5～0.25kPa.The ultrafiltration initial stage is adopted lower pressure, slowly boosts then; In ultra-filtration process, adopt the periodic pressure fluctuation, the pressure wave moment is 0.1～0.2Mpa.
(2) the feed liquid flow velocity is 1.0～4.0m/s, is preferably 2.0～3.0m/s.In the ultra-filtration process, adopt the fluctuation of periodicity flow so that produce pulsating flow or non-stationary flow in membrane channels, the flow speed wave moment is 1.0～2.0m/s.
(3) feed high-pressure inert gas such as nitrogen in the ultrafiltration system discontinuous, form the gas-liquid stream of pulses, the cycle is that 0.5h～2h ventilates once, each 1 minute.
(3) feed temperature is 15～50 ℃, is preferably 20～40 ℃.
(4) when feed liquid stock solution is concentrated 1/15～1/5, add water or dilute alcohol solution ultrafiltration 1～2 time again; Be preferably when feed liquid stock solution is concentrated 1/12～1/8, add water or dilute alcohol solution ultrafiltration 1～2 time again.
(5) pH value of feed liquid is controlled at 5～9, is preferably 6.0～7.5;
(6) backwash condition: backwashing pressure is 0.15～2.5MPa, and backwashing period is that 0.5～1.5h, backwashing time are 1min～10min.When ultrafiltration module use in parallel is replaced the method for recoil, wherein a cover or a few cover carry out normal ultrafiltration and distribute the recoil ultrafilter membrane of another set of or several grip assemblies of a part of filtrate, exchange is carried out behind the certain interval of time, generally is work 10～20min, recoil 30sec～3min.
(7) the Chemical cleaning cycle is 0.5 month～2 months, the Chemical cleaning medicament is generally diluted acid, diluted alkaline, surfactant, be preferably for example 0.5%～4.0% sodium hydroxide of diluted alkaline, the mixed solution of 1.5% sodium hydroxide and 2% sodium hypochlorite etc., pH value is 10～12, and cleaning pressure is 0.05～1.0MPa.After cleaning with chemical, the flushing of reuse water is near neutral.
In ultra-filtration process, both periodic pressure oscillation or the fluctuation of periodicity flow or periodicity fed noble gas separately, also can unite use, be periodic pressure fluctuation and periodically flow fluctuation associating use, perhaps the periodic pressure fluctuation is with periodically feeding noble gas unites use, perhaps periodically the flow fluctuation is with periodically feeding noble gas unites use, and perhaps the three unites use together.
In the step (d), with ultrafiltrate be condensed into behind the extractum directly with any or more than one pharmaceuticss on the adjuvant accepted mixed evenly after, or with Borneolum Syntheticum or Lignum Dalbergiae Odoriferae oil or Styrax or Moschus or muscone and any or more than one pharmaceuticss on the adjuvant accepted is mixed can be made into tablet, capsule, granule, oral liquid, slow releasing preparation, controlled release preparation, gel, ointment, ointment, cream, suppository, injection, injectable powder, patch, drop pill, suspensoid after evenly, or the like; Be preferably tablet, capsule, granule, injection, drop pill; The best is a drop pill.
Drop pill of the present invention is prepared from as active component and adjuvant by above-mentioned Chinese medicine composition, perhaps is prepared from as active component and substrate adjuvant and plasticity adjuvant by above-mentioned Chinese medicine composition.
The substrate adjuvant of drop pill can be used Polyethylene Glycol, can be one or more the mixture in cetomacrogol 1000, polyethylene glycol 1500, Macrogol 4000, the polyethylene glycol 6000; Preferred Macrogol 4000, polyethylene glycol 6000; The best is a polyethylene glycol 6000; Addition is 2～10 times of extractum weight.
The preferred for preparation method is: after step (d) ultrafiltrate is condensed into extractum, directly with adjuvant or with Borneolum Syntheticum or Lignum Dalbergiae Odoriferae oil or Styrax or Moschus or muscone and adjuvant mixed even after, add the transconversion into heat material, move into the jar that drips of drop pill machine, medicine liquid droplet is to condensed fluid such as liquid paraffin or methyl-silicone oil, remove condensed fluid, select ball.
Wherein: adjuvant is a Polyethylene Glycol-6000, and 53～58 ℃ of its condensation points, addition are extractum or extractum and Borneolum Syntheticum or Lignum Dalbergiae Odoriferae oil or Styrax or Moschus or muscone weight 2～6 times; Changing the material temperature is 60～100 ℃; The temperature of condensed fluid is 0～10 ℃, and the best is 5～10 ℃; Ball heavily is 5～50mg/ grain, diameter 1.95～4.29mm.
The substrate adjuvant of drop pill preferably from natural, the substrate adjuvant of plant origin particularly, also can contain the plasticity composition in this substrate adjuvant.Specifically, the substrate adjuvant is selected from following one or more adjuvant: at least a substrate adjuvant in pharmaceutically useful monosaccharide, oligosaccharide, polysaccharide, sugar ester, sugar alcohol, fruit acid, advanced higher fatty acid derivative, high fatty alcohol, polyhydric alcohol, carbamide, the polyethylene oxide derivant.
In the above-mentioned substance, monosaccharide such as D-ribose, fructose, glucose, xylose; Oligosaccharide such as trehalose, Raffinose, maltose; Polysaccharide such as agarose; Sugar ester such as sucrose ester, D-ribonic acid-gamma lactone; Sugar alcohol such as erythritol, sorbitol, xylitol, arabitol, isomalt, lactose; Fruit acid such as malic acid, citric acid; Advanced higher fatty acid derivative such as sodium stearate, tristerin, tripalmitin, Lac; High fatty alcohol such as hexadecanol, octadecanol; Polyhydric alcohol such as phenylglycol; Polyethylene oxide derivant such as polyoxyethylene monostearate, polyoxyethylene alkyl ether, and above-claimed cpd contain water of crystallization chemical compound etc.In the above material, the natural adjuvant of plant origin such as erythritol, sorbitol, fructose, D-ribonic acid-gamma lactone, arabitol, trehalose, D-ribose, low melting-point agarose, Lac, xylitol, Raffinose, glucose, malic acid, citric acid, isomalt, lactose, maltose, xylose, sucrose ester etc., and they contain the water of crystallization chemical compound; Chemosynthesis adjuvant and animal origin adjuvant such as phenylglycol, Polyethylene Glycol, hexadecanol, octadecanol, sodium stearate, tristerin, tripalmitin, carbamide, polyoxyethylene monostearate, polyoxyethylene alkyl ether.In the above-mentioned substance, especially preferably from following one or more adjuvant: sorbitol, xylitol, lactose, maltose, sucrose ester, and they contain the water of crystallization chemical compound.
Above-mentioned substrate adjuvant is mainly the natural adjuvant of plant origin, and the content that is meant the adjuvant of plant origin in adjuvant is more than 50 weight %, and the content of chemosynthesis adjuvant and animal origin adjuvant is no more than the natural adjuvant of plant origin.Preferably, the substrate adjuvant of drop pill of the present invention only uses the natural adjuvant of plant origin, perhaps is mainly the natural adjuvant of plant origin and only contains a spot of chemosynthesis adjuvant and animal origin adjuvant, and its content is below 50 weight %, below the preferred 40 weight %, more preferably below the 30 weight %.The natural adjuvant of above-described so-called plant origin is meant as adjuvant itself and extracts in plant cell or tissue, or by the material of plant extract through modifications such as derivatizations after the product of gained.So-called chemosynthesis adjuvant is meant synthetic micromolecule or the macromolecular compound that is obtained through chemical synthesis process by simple micromolecule.The natural adjuvant of so-called animal origin is meant as adjuvant itself and extracts in the animal cell or tissue, or the material that extracts by animal through modifications such as derivatizations after the product of gained.
The substrate adjuvant of above-mentioned plant origin, have now or in the future may have the synthetic product, if the synthetic product are identical or close with the character of the natural substrates adjuvant of original plant origin, characteristic with safety non-toxic, then the natural substrates adjuvant of alternative plant origin is used as the natural substrates adjuvant of above-mentioned plant origin.
For improving the formability of drop pill of the present invention, preferably also contain the plasticity composition in the adjuvant of drop pill of the present invention.As this plasticity composition, for example can enumerate and be selected from following one or more composition: the natural adjuvant of plant origin such as starch and derivant, cellulose and derivant thereof, arabic gum, dextran, chitin, sesbania gum, carrageenan, Ficus elastica, Furcellaran, tragakanta, carrageenin, tamarind gum, pectin, xanthan gum, alginic acid and salt thereof, dextrin, cyclodextrin, agar, lactose; Chemosynthesis adjuvant and animal origin adjuvant such as polyvinylpyrrolidone, crospolyvinylpyrrolidone, carbomer, polyvinyl alcohol, acrylic resin, poloxamer, silicon dioxide, gelatin etc.
Above-mentioned starch and derivant thereof such as pregelatinized Starch, modified starch, hydroxypropyl starch, carboxymethyl starch etc.Described cellulose and derivant thereof such as methylcellulose, microcrystalline Cellulose, sodium carboxymethyl cellulose, hydroxypropyl emthylcellulose, cross-linking sodium carboxymethyl cellulose, hydroxyethylmethyl-cellulose, hydroxyethyl-cellulose, hydroxypropyl cellulose.
In the plasticity composition, preferably from following one or more adjuvant: pregelatinized Starch, carboxymethyl starch, methylcellulose, sodium carboxymethyl cellulose, hydroxypropyl emthylcellulose, arabic gum, alginic acid, dextrin, cyclodextrin, agar, lactose.In addition, glyceryl monostearate, polyoxyethylene monostearate also can be used as the plasticity composition and other substrate supplementary product compatibility is used.
The composition of above-described so-called plant origin is meant as adjuvant itself and extracts in plant cell or tissue, or by the material of plant extract through modifications such as derivatizations after the product of gained.So-called chemosynthesis adjuvant is meant synthetic micromolecule or the macromolecular compound that is obtained through chemical synthesis process by simple micromolecule.The adjuvant of so-called animal origin is meant as adjuvant itself and extracts in the animal cell or tissue, or the material that extracts by animal through modifications such as derivatizations after the product of gained.
The plasticity composition of above-mentioned plant origin, have now or in the future may have the synthetic product, if the synthetic product are identical or close with the character of the natural plasticity composition of plant origin, characteristic with safety non-toxic, then the natural plasticity composition of alternative above-mentioned plant origin is used as the natural plasticity substrate adjuvant of above-mentioned plant origin.
The above-mentioned monosaccharide that is selected from, oligosaccharide, polysaccharide, sugar ester, sugar alcohol, fruit acid, advanced higher fatty acid derivative, high fatty alcohol, polyhydric alcohol, carbamide, the substrate adjuvant of polyethylene oxide derivant etc., the substrate adjuvant and the above-mentioned plasticity composition in preferred plant source are selected collocation according to medicinal property, it is preferably arranged in pairs or groups and is xylitol and starch, lactose and starch, xylitol and arabic gum, sucrose ester and glyceryl monostearate, sucrose ester and polyoxyethylene monostearate, sucrose ester and polyoxyethylene monostearate and cross-linking sodium carboxymethyl cellulose, sucrose ester and polyoxyethylene monostearate and cross-linking sodium carboxymethyl cellulose and silicon dioxide etc., but be not limited thereto.
The weight ratio of above-mentioned substrate adjuvant and plasticity composition is 1: 0～1: 1.5, is preferably 1: 0.1～1: 0.9, and the best is 1: 0.1～1: 0.5.
In the above-mentioned substrate adjuvant, xylitol is preferably 1: 0.2 with the ratio of the weight of starch～and 1: 0.3;
In the above-mentioned substrate adjuvant, lactose is preferably 1: 0.2 with the ratio of the weight of starch～and 1: 0.3;
In the above-mentioned substrate adjuvant, the ratio of the weight of xylitol and arabic gum is preferably 1: 0.2～and 1: 0.4;
In the above-mentioned substrate adjuvant, the weight ratio of sucrose ester and glyceryl monostearate is 1: 0.1～1: 1, and the best is 1: 0.5.
In the above-mentioned substrate adjuvant, the weight ratio of sucrose ester and polyoxyethylene monostearate is 1: 0.1 to 1: 1, and the best is 1: 0.5.
In the above-mentioned substrate adjuvant, the weight ratio of sucrose ester and polyoxyethylene monostearate and cross-linking sodium carboxymethyl cellulose is 1: (0.1～1): (0.1～1), the best are 1: 0.4: 0.6.
In the above-mentioned substrate adjuvant, the weight ratio of sucrose ester and polyoxyethylene monostearate and cross-linking sodium carboxymethyl cellulose and silicon dioxide is 15: (7～15): (0.1～2): (0.1～2), the best are 15: 11: 1: 1.
Above-mentioned drop pill substrate adjuvant is 1: 0.1～1: 1 with the ratio of the weight of extractum, is preferably 1: 0.1～1: 0.6, and the best is 1: 0.2～1: 0.4.
The preferred for preparation process conditions are: extractum mixes mixing time with the substrate adjuvant be 10～30 minutes; A mixed heating and melting temperature of extractum and substrate adjuvant or a system temperature are 45～95 ℃, are preferably 60～95 ℃; Liquid coolant is liquid paraffin, methyl-silicone oil or vegetable oil (Oleum Glycines, Semen Ricini wet goods) etc., is preferably liquid paraffin, methyl-silicone oil; The temperature of liquid coolant is-20～30 ℃, is preferably 0～18 ℃; Dropper mouth internal diameter is 1.0～4.0mm, is preferably 1.2～2.5mm; The difference of dropper mouth external diameter and internal diameter is less for well.
Below by medicine of the present invention the experiment of the protective effect of Ischemia and Reperfusion in vivo in Rats myocardial damage is illustrated its beneficial effect.
1. animal model: Wistar strain male rat, open chest anesthetized is kept breathing, around left coronary artery, and carries out ligation between left auricle and pulmonary conus.
2. method: rat is divided into 4 groups at random: 1. sham operated rats (sham-operated control), normal saline is irritated stomach, 1ml/ days, totally 4 days; 2. myocardial ischemia-reperfusion group (M-IR), it is the same to irritate the stomach method; 3. FUFANG DANSHEN PIAN group (with reference to the preparation of the method for 2000 editions FUFANG DANSHEN PIAN of Chinese Pharmacopoeia) was dissolved in the 1ml normal saline with 2g crude drug/kg/ days, and it is the same to irritate the stomach method; 4. medicine group of the present invention (press embodiment 6 method preparation and extractum), be dissolved in the 1ml normal saline with 2g crude drug/kg/ days, it is the same to irritate the stomach method.Not ligation of sham operated rats; Other group is in ligation perfusion again after 1 hour.Take out after injecting 1% her Wen orchid in the ligation left coronary artery once more before sacrifice of animal, ventricle, with the PBS rinsing, freezing 1 hour.After removing unnecessary tissue, 30 minutes (37 ℃) of dyeing in 1%TTC.With weight method calculating myocardium ischemia hazardous area (she does not dye the district by the Wen orchid), infarcted region (TTC does not dye the district).
3. the result of variations of myocardial infarct size
The myocardial infarction phenomenon was not seen in sham-operation in 7 hours; It is obvious that myocardial ischemia poured into after 6 hours myocardial infarction in 1 hour again; Medicine of the present invention can obviously dwindle the myocardial infarct size of myocardial reperfusion rat, shows that medicine of the present invention pours into the myocardium cell necrosis variation again to ischemic myocardial cells good protective action (seeing Table 1) is arranged.
Table 1 is respectively organized the variation of myocardial infarct size
| Group | Example number (n) | Infarcted region weight/left ventricular mass (%) | Infarcted region weight/hazardous area weight (%) |
| Sham-control group M-IR group FUFANG DANSHEN PIAN group medicine group of the present invention | 10 10 10 10 | 0 41.3±7.6 34.6±7.0* 27.5±6.7** | 0 63.4±8.3 53.4±7.6* 45.4±8.3** △ |
Annotate: compare * P＜0.05, material P＜0.01 with the M-IR group; Compare with the FUFANG DANSHEN PIAN group,
△P＜0.05,
△ △P＜0.01.
The specific embodiment
The invention will be further elaborated below in conjunction with embodiment.These embodiment only are used to the purpose that exemplifies, rather than limit the present invention by any way.
Embodiment 1
Crude drug adopts Radix Salviae Miltiorrhizae 97g, Radix Notoginseng 79g, Fructus Aurantii 35g, Lignum Dalbergiae Odoriferae oil 3g, Radix Ginseng 40g
Radix Salviae Miltiorrhizae, Radix Notoginseng, Fructus Aurantii and people participate in 5 times of water gagings, decoct 2 hours, filter, and filtering residue carries out the second time and extracts, and adds 4 times of water gagings, fries in shallow oil 1 hour, filters, and filtering residue discards, merging filtrate.Filtrate decompression is concentrated into medicine liquid volume (L) and medical material weight (Kg) than being 1: 0.9～1.1, adds ethanol and makes medicinal liquid contain determining alcohol 70%, leaves standstill, and filters, and filtrate is concentrated to obtain the extractum that relative density is 1.32～1.40 (55 ℃).Add Lignum Dalbergiae Odoriferae oil, drying is made granule, and compacting is in blocks, or sugar coating, promptly.
Embodiment 2
Radix Salviae Miltiorrhizae 100g, Radix Notoginseng 10g, Fructus Aurantii 15g;
Radix Salviae Miltiorrhizae, Radix Notoginseng, Fructus Aurantii are used 70%7 ethanol extractions, and extracting solution carries out microfiltration with ceramic membrane, collect filtrate; The filtrate ultrafiltration, the operating condition of ultrafiltration technology is: the inlet pressure of ultrafiltration is 0.35Mpa, the liquid outlet pressure ratio inlet pressure of ultrafiltration hangs down 0.20kPa.The ultrafiltration initial stage is adopted lower pressure, slowly boosts then; In ultra-filtration process, adopt the periodic pressure fluctuation, the pressure wave moment is 0.2Mpa.The feed liquid flow velocity is 3.0m/s, in the ultra-filtration process, adopts periodically flow fluctuation so that produce pulsating flow or non-stationary flow in membrane channels, the flow speed wave moment is 2.0m/s, feeds nitrogen in the ultrafiltration system discontinuous, forms the gas-liquid stream of pulses, cycle is that 2h ventilates once each 1 minute.Feed temperature is 40 ℃, when feed liquid stock solution is concentrated 1/8, adds water or dilute alcohol solution ultrafiltration 2 times again, and the pH value of feed liquid is controlled at 7.5.
Ultrafiltrate concentrates and to obtain the extractum that relative density is 1.35～1.39 (55 ℃), adds 3% polyvidone alcoholic solution system soft material, crosses 18 mesh sieve system granules, 60 ℃ of dryings 30～45 minutes, and granulate, the adding Pulvis Talci, mixing fills in capsule, promptly.Embodiment 3
Crude drug Radix Salviae Miltiorrhizae 20g, Radix Notoginseng 2g, Fructus Aurantii 10g, Radix Angelicae Sinensis 100g, Borneolum Syntheticum 2.2g.
Radix Salviae Miltiorrhizae, Radix Notoginseng, Fructus Aurantii and Radix Angelicae Sinensis add 5 times of water gagings, decoct 2 hours, filter, and filtering residue carries out the second time and extracts, and adds 4 times of water gagings, fries in shallow oil 1 hour, filters, and filtering residue discards, merging filtrate.Filtrate decompression is concentrated into medicine liquid volume (L) and medical material weight (Kg) than being 1: 0.9～1.1, adds ethanol and makes medicinal liquid contain determining alcohol 70%, leaves standstill, and filters, and filtrate is concentrated to obtain the extractum that relative density is 1.32～1.40 (55 ℃).With extractum and Borneolum Syntheticum in the batch (-type) fluid bed with the lactose fluidisation, drying is made granule, promptly.
Embodiment 4
Crude drug Radix Salviae Miltiorrhizae 485g, Radix Notoginseng 70g, Fructus Aurantii 150g, muscone 2.2g, Radix Codonopsis 50g.
Radix Salviae Miltiorrhizae, Radix Notoginseng, Fructus Aurantii and Radix Codonopsis add 5 times of water gagings, decoct 2 hours, filter, and filtering residue carries out the second time and extracts, and adds 4 times of water gagings, fries in shallow oil 1 hour, filters, and filtering residue discards, merging filtrate.Filtrate decompression is concentrated into medicine liquid volume (L) and medical material weight (Kg) than being 1: 0.9～1.1, adds ethanol and makes medicinal liquid contain determining alcohol 75%, leaves standstill filtration; Filtrate is that 6000 three cellulose acetate membrane carries out ultrafiltration with molecular cut off, and filter type adopts cross flow filter.The operating condition of ultrafiltration technology is: the inlet pressure of ultrafiltration is 0.1Mpa, and the liquid outlet pressure ratio inlet pressure of ultrafiltration hangs down 0.5kPa.The ultrafiltration initial stage is adopted lower pressure, slowly boosts then; In ultra-filtration process, adopt the periodic pressure fluctuation, the pressure wave moment is 0.1Mpa.The feed liquid flow velocity is 1.0m/s, in the ultra-filtration process, adopts periodically flow fluctuation so that produce pulsating flow or non-stationary flow in membrane channels, the flow speed wave moment is 1.0m/s, feeds nitrogen in the ultrafiltration system discontinuous, forms the gas-liquid stream of pulses, cycle is that 0.5h ventilates once each 1 minute.Feed temperature is 15 ℃, when feed liquid stock solution is concentrated 1/15, adds water or dilute alcohol solution ultrafiltration 1 time again, and the pH value of feed liquid is controlled at 5.Backwashing pressure is 0.15MPa, and backwashing period is that 0.5h, backwashing time are 1min.When with the in parallel method of using alternately recoil of ultrafiltration module, wherein a cover or a few cover carry out normal ultrafiltration and distribute the recoil ultrafilter membrane of another set of or several grip assemblies of a part of filtrate, and exchange is carried out behind the certain interval of time, work 10min, recoil 30sec.The Chemical cleaning cycle is 0.5 month, and the Chemical cleaning medicament is the mixed solution of 0.5%～4.0% sodium hydroxide, 1.5% sodium hydroxide and 2% sodium hypochlorite, and pH value is 10～12, and cleaning pressure is 0.05MPa.After cleaning with chemical, the flushing of reuse water is near neutral.
Ultrafiltrate concentrates and obtains the extractum that relative density is 1.32～1.40 (55 ℃), adds muscone, and mix homogeneously adds mannitol 30g, calcium disodium edetate 5g, distilled water 5ml, behind the said components mixing, and lyophilization, packing, promptly.
Embodiment 5
Crude drug Radix Salviae Miltiorrhizae 180g, Radix Notoginseng 50g, Fructus Aurantii 50g, Styrax 4g.
Radix Salviae Miltiorrhizae, Radix Notoginseng and Fructus Aurantii add 5 times of water gagings, decoct 2 hours, filter, and filtering residue carries out the second time and extracts, and adds 4 times of water gagings, fries in shallow oil 1 hour, filters, and filtering residue discards, merging filtrate.Filtrate decompression is concentrated into medicine liquid volume (L) and medical material weight (Kg) than being 1: 1.1～1.2, adds ethanol and makes medicinal liquid contain determining alcohol 70%, leaves standstill, and filters, and filtrate is concentrated to obtain the extractum that relative density is 1.32～1.40 (55 ℃).Get that extractum, Styrax and Polyethylene Glycol-6000 18g are mixed evenly to be heated to 85 ℃ of temperature, change material after 30 minutes, move in the dropping-pill machine jar that jar temperature remains on 85 ℃; In medicine liquid droplet to the 7 ℃ liquid paraffin, take out drop pill, oil removing, screen cloth selects ball, makes 1000 drop pill, promptly.
Embodiment 6
Crude drug Radix Salviae Miltiorrhizae 97g, Radix Notoginseng 79g, Fructus Aurantii 35g.
Radix Salviae Miltiorrhizae, Radix Notoginseng, Fructus Aurantii add 5 times of water gagings, decoct 2 hours, filter, and filtering residue carries out the second time and extracts, and adds 4 times of water gagings, fries in shallow oil 1 hour, filters, and filtering residue discards, merging filtrate.Is that 50000 sulfonated polysulfone membrane carries out ultrafiltration with filtrate with molecular cut off, and filter type adopts cross flow filter.The operating condition of ultrafiltration technology is: the inlet pressure of ultrafiltration is 0.35Mpa, and the liquid outlet pressure ratio inlet pressure of ultrafiltration hangs down 0.20kPa.The ultrafiltration initial stage is adopted lower pressure, slowly boosts then; In ultra-filtration process, adopt the periodic pressure fluctuation, the pressure wave moment is 0.2Mpa.The feed liquid flow velocity is 3.0m/s, in the ultra-filtration process, adopts periodically flow fluctuation so that produce pulsating flow or non-stationary flow in membrane channels, the flow speed wave moment is 2.0m/s, feeds nitrogen in the ultrafiltration system discontinuous, forms the gas-liquid stream of pulses, cycle is that 2h ventilates once each 1 minute.Feed temperature is 40 ℃, when feed liquid stock solution is concentrated 1/8, adds water or dilute alcohol solution ultrafiltration 2 times again, and the pH value of feed liquid is controlled at 7.5.Backwashing pressure is 2.5MPa, and backwashing period is that 1.5h, backwashing time are 10min.When with the in parallel method of using alternately recoil of ultrafiltration module, wherein a cover or a few cover carry out normal ultrafiltration and distribute the recoil ultrafilter membrane of another set of or several grip assemblies of a part of filtrate, and exchange is carried out behind the certain interval of time, work 20min, recoil 3min.The Chemical cleaning cycle is 2 months, and the Chemical cleaning medicament is the mixed solution of 0.5%～4.0% sodium hydroxide, 1.5% sodium hydroxide and 2% sodium hypochlorite, and pH value is 10～12, and cleaning pressure is 1.0MPa.After cleaning with chemical, the flushing of reuse water is near neutral.
Described ultrafiltrate concentrated obtain the extractum that relative density is 1.35～1.39 (55 ℃).Get that extractum and Polyethylene Glycol-6000 20g are mixed evenly to be heated to 60 ℃ of temperature, change material after 40 minutes, move in the dropping-pill machine jar that jar temperature remains on 90 ℃.In medicine liquid droplet to the 8 ℃ methyl-silicone oil, take out drop pill, oil removing, screen cloth selects ball, makes 1000 drop pill, promptly.
Embodiment 7
Crude drug Radix Salviae Miltiorrhizae 15g, Radix Notoginseng 4.5g, Fructus Aurantii 2g, Lignum Dalbergiae Odoriferae oil 0.25g, adjuvant lactose 18.0g, pregelatinized Starch 4.5g.
The Radix Salviae Miltiorrhizae of coarse pulverization, Radix Notoginseng, Fructus Aurantii medical material to extraction pot, are added 5 times of water gagings, decocted 2 hours, filter, filtering residue carries out second time and extracts, and adds 4 times of water gagings, fried in shallow oil 1 hour, and filtration, filtering residue discards, merging filtrate.Filtrate decompression is concentrated into medicine liquid volume (L) and medical material weight (Kg) than being 1: 0.9～1.1, adds ethanol and makes medicinal liquid contain determining alcohol 70%, leaves standstill, and filters, and filtrate is concentrated to obtain the extractum that relative density is 1.32～1.40 (55 ℃).
Get above-mentioned extractum and Lignum Dalbergiae Odoriferae oil, evenly mixed with adjuvant lactose and pregelatinized Starch, be heated to 60 ℃ of temperature, change material after 30 minutes, move in the dropping-pill machine jar that jar temperature remains on 90 ℃.In medicine liquid droplet to the 7 ℃ liquid paraffin, take out drop pill, oil removing, screen cloth selects ball, promptly.The result shows, prepared drop pill rounding, even, consistent, the no adhesion phenomenon of color and luster of size.
The drop pill (newly) that the new substrate adjuvant of above-mentioned usefulness is made with polyethylene glycol 6000 be the adjuvant dissolve scattered time limit of making drop pill (embodiment 6), weight differential comparison (seeing the following form)
| 0 month | January | February | March | June | December | 18 months | |||
| Criterion | The result | ||||||||
| 1 batch | Weight differential (± 15%) | New and old | All in 10% | All in 10% | All in 10% | All in 10% | All in 10% | All in 10% | All in 10% |
| Dissolve scattered time limit (30 minutes) | New and old | 2′ 83″ 4′ 52″ | 2′ 83″ 4′ 52″ | 2′ 83″ 4′ 52″ | 2′ 83″ 4′ 53″ | 2′ 85″ 4′ 53″ | 2′ 87″ 4′ 55″ | 2′ 89″ 4′ 56″ | |
| 2 batches | Weight differential (± 15%) | New and old | All in 10% | All in 10% | All in 10% | All in 10% | All in 10% | All in 10% | All in 10% |
| Dissolve scattered time limit (30 minutes) | New and old | 2′ 84″ 4′ 53″ | 2′ 84″ 4′ 53″ | 2′ 84″ 4′ 53″ | 2′ 85″ 4′ 54″ | 2′ 85″ 4′ 54″ | 2′ 86″ 4′ 55″ | 2′ 87″ 4′ 57″ | |
| 3 batches | Weight differential (± 15%) | New and old | All in 10% | All in 10% | All in 10% | All in 10% | All in 10% | All in 10% | All in 10% |
| Dissolve scattered time limit (30 minutes) | New and old | 2′ 85″ 4′ 53″ | 2′ 85″ 4′ 53″ | 2′ 85″ 4′ 53″ | 2′ 86″ 4′ 54″ | 2′ 86″ 4′ 55″ | 2′ 87″ 4′ 57″ | 2′ 88″ 4′ 58″ |
Above test data shows, the molten diffusing speed of the Chinese medicine dripping pills made from new substrate adjuvant of the present invention is faster, is more conducive to medicine and plays a role in the shortest time; The ball method of double differences is different all to be controlled in the pharmacopeia prescribed limit, and the alternative present chemosynthesis adjuvant of this natural substrates adjuvant is described, carries out suitability for industrialized production.
Embodiment 8
Crude drug Radix Salviae Miltiorrhizae 24.2g, Radix Notoginseng 25.5g, Fructus Aurantii 25.4g, Moschus 0.35g, Herba Leonuri 10.0g; Adjuvant xylitol 15.0g, starch 5.0g.
Learn from else's experience Radix Salviae Miltiorrhizae, Radix Notoginseng, Fructus Aurantii and the Herba Leonuri medical material of coarse pulverization to extraction pot, add the 0.9g sodium bicarbonate, add 4 times of water gagings, decocted 2 hours, filter, filtering residue carries out extraction second time, adds 4 times of water gagings, decocted 1 hour, and filtration, filtering residue discards, merging filtrate.Filtrate decompression is concentrated into medicine liquid volume (L) and medical material weight (Kg) than being 1: 0.9～1.1, adds ethanol and makes medicinal liquid contain determining alcohol 75%, leaves standstill, and filters, and filtrate is concentrated to obtain the extractum that relative density is 1.32～1.40 (55 ℃).
Get above-mentioned extractum and Moschus, evenly mixed with adjuvant xylitol and starch, be heated to 65 ℃ of temperature, change material after 30 minutes, move in the dropping-pill machine jar that jar temperature remains on 85 ℃.In medicine liquid droplet to the 8 ℃ liquid paraffin, take out drop pill, oil removing, screen cloth selects ball, promptly.The result shows, prepared drop pill rounding, even, consistent, the no adhesion phenomenon of color and luster of size.By measuring under Chinese Pharmacopoeia version in 2000 the method disintegration item, the result does not add the average 2.78min of baffle plate by screen cloth, meets the pharmacopeia regulation this disintegration.
Embodiment 9
Crude drug Radix Salviae Miltiorrhizae 16.2g, Radix Notoginseng 29.5g, Fructus Aurantii 20.5g, Styrax 0.31g, Radix Astragali 13.8g; Adjuvant lactose 15.0g, arabic gum 3.0g.
With ethanol extraction Radix Salviae Miltiorrhizae, Radix Notoginseng, Fructus Aurantii and Milkvetch Root, obtain Radix Salviae Miltiorrhizae, Radix Notoginseng, Fructus Aurantii and Radix Astragali ethanol extract, with this extracting liquid filtering, collect filtrate with gauze.Filtrate is that 20000 cellulose diacetate film carries out ultrafiltration with molecular cut off, and ultrafiltrate concentrates and obtains the extractum that relative density is 1.35～1.39 (55 ℃).The condition of above-mentioned ultrafiltration is: the inlet pressure of ultrafiltration is 0.35Mpa, and the liquid outlet pressure ratio inlet pressure of ultrafiltration hangs down 0.20kPa.The ultrafiltration initial stage is adopted lower pressure, slowly boosts then; In ultra-filtration process, adopt the periodic pressure fluctuation, the pressure wave moment is 0.2Mpa.The feed liquid flow velocity is 3.0m/s, in the ultra-filtration process, adopts periodically flow fluctuation so that produce pulsating flow or non-stationary flow in membrane channels, the flow speed wave moment is 2.0m/s, feeds nitrogen in the ultrafiltration system discontinuous, forms the gas-liquid stream of pulses, cycle is that 2h ventilates once each 1 minute.Feed temperature is 40 ℃, when feed liquid stock solution is concentrated 1/8, adds the water ultrafiltration again 2 times, and the pH value of feed liquid is controlled at 7.5.
Get above-mentioned extractum and Styrax, evenly mixed with adjuvant lactose and arabic gum, be heated to 60 ℃ of temperature, change material after 30 minutes, move in the dropping-pill machine jar that jar temperature remains on 85 ℃.In medicine liquid droplet to the 6 ℃ liquid paraffin, take out drop pill, oil removing, screen cloth selects ball, promptly.The result shows, prepared drop pill rounding, even, consistent, the no adhesion phenomenon of color and luster of size.By measuring under Chinese Pharmacopoeia version in 2000 the method disintegration item, the result does not add the average 2.61min of baffle plate by screen cloth, meets the pharmacopeia regulation this disintegration.
Embodiment 10
Crude drug Radix Salviae Miltiorrhizae 46.5g, Radix Notoginseng 5.0g, Fructus Aurantii 10.5g, Borneolum Syntheticum 0.57g, Radix Ginseng 5.5g; Adjuvant xylitol 16.0g, tragakanta 5.0g.
Radix Salviae Miltiorrhizae, Radix Notoginseng, Fructus Aurantii and the people of coarse pulverization are participated in 5 times of water gagings, decocted 2 hours, filter, filtering residue carries out the second time and extracts, add 4 times of water gagings, fried in shallow oil 1 hour, filter, filtering residue discards, merging filtrate gets Radix Salviae Miltiorrhizae, Radix Notoginseng, Fructus Aurantii and Radix Ginseng extractive solution, leaves standstill, and filters.Filtrate is that 60000 polysulfone membrane is carried out ultrafiltration with molecular cut off, and ultrafiltrate concentrates and obtains the extractum that relative density is 1.35～1.39 (55 ℃).The operating condition of ultrafiltration technology is: the inlet pressure of ultrafiltration is 0.35Mpa, and the liquid outlet pressure ratio inlet pressure of ultrafiltration hangs down 0.20kPa.The ultrafiltration initial stage is adopted lower pressure, slowly boosts then; In ultra-filtration process, adopt the periodic pressure fluctuation, the pressure wave moment is 0.2Mpa.The feed liquid flow velocity is 3.0m/s, in the ultra-filtration process, adopts periodically flow fluctuation so that produce pulsating flow or non-stationary flow in membrane channels, the flow speed wave moment is 2.0m/s, feeds nitrogen in the ultrafiltration system discontinuous, forms the gas-liquid stream of pulses, cycle is that 2h ventilates once each 1 minute.Feed temperature is 40 ℃, when feed liquid stock solution is concentrated 1/8, adds the dilute alcohol solution ultrafiltration again 2 times, and the pH value of feed liquid is controlled at 7.5.
Get above-mentioned extractum and Borneolum Syntheticum, evenly mixed with adjuvant xylitol and tragakanta, be heated to 60 ℃ of temperature, change material after 25 minutes, move in the dropping-pill machine jar that jar temperature remains on 89 ℃.In medicine liquid droplet to the 5 ℃ liquid paraffin, take out drop pill, oil removing, screen cloth selects ball, promptly.The result shows, prepared drop pill rounding, even, consistent, the no adhesion phenomenon of color and luster of size.By measuring under Chinese Pharmacopoeia version in 2000 the method disintegration item, the result does not add the average 2.62min of baffle plate by screen cloth, meets the pharmacopeia regulation this disintegration.
Embodiment 11
Crude drug Radix Salviae Miltiorrhizae 46.5g, Radix Notoginseng 3.0g, Fructus Aurantii 3.0g, Radix Ginseng 8.5g; Adjuvant sucrose ester 10.0g, polyoxyethylene monostearate 8.0g.
With 80% ethanol extraction Radix Salviae Miltiorrhizae, Radix Notoginseng, Fructus Aurantii and Radix Ginseng, obtain the ethanol extract of Radix Salviae Miltiorrhizae, Radix Notoginseng, Fructus Aurantii and Radix Ginseng, get supernatant with dividing behind this extracting solution high speed centrifugation.With this liquid molecular cut off is that 50000 sulfonated polysulfone membrane carries out ultrafiltration, and ultrafiltrate concentrates and obtains the extractum that relative density is 1.35～1.39 (55 ℃).The operating condition of ultrafiltration technology is: the inlet pressure of ultrafiltration is 0.5Mpa, and the liquid outlet pressure ratio inlet pressure of ultrafiltration hangs down 0.25kPa.The ultrafiltration initial stage is adopted lower pressure, slowly boosts then; In ultra-filtration process, adopt the periodic pressure fluctuation, the pressure wave moment is 0.2Mpa.The feed liquid flow velocity is 4.0m/s, in the ultra-filtration process, adopts periodically flow fluctuation so that produce pulsating flow or non-stationary flow in membrane channels, the flow speed wave moment is 2.0m/s, feeds nitrogen in the ultrafiltration system discontinuous, forms the gas-liquid stream of pulses, cycle is that 2h ventilates once each 1 minute.Feed temperature is 50 ℃, when feed liquid stock solution is concentrated 1/5, adds the water ultrafiltration again 2 times, and the pH value of feed liquid is controlled at 9.
Get that above-mentioned extractum and adjuvant sucrose ester and polyoxyethylene monostearate are mixed evenly to be heated to 60 ℃ of temperature, change material after 30 minutes, move in the dropping-pill machine jar that jar temperature remains on 90 ℃.In medicine liquid droplet to the 5 ℃ liquid paraffin, take out drop pill, oil removing, screen cloth selects ball, promptly.The result shows, prepared drop pill rounding, even, consistent, the no adhesion phenomenon of color and luster of size.By measuring under Chinese Pharmacopoeia version in 2000 the method disintegration item, the result does not add the average 2.64min of baffle plate by screen cloth, meets the pharmacopeia regulation this disintegration.
Embodiment 12
Crude drug Radix Salviae Miltiorrhizae 49.0g, Radix Notoginseng 16.5g, Fructus Aurantii 17.5g, Radix Angelicae Sinensis 6.0g; Adjuvant sucrose ester 15.0g, glyceryl monostearate 4.0g.
Radix Salviae Miltiorrhizae, Radix Notoginseng, Fructus Aurantii and the Radix Angelicae Sinensis medical material of coarse pulverization to extraction pot, added 5 times of water gagings, decocted 2 hours, filter, filtering residue carries out second time and extracts, and adds 4 times of water gagings, fried in shallow oil 1 hour, and filtration, filtering residue discards, merging filtrate.Filtrate is that 60000 poly (ether sulfone) film carries out ultrafiltration with molecular cut off, and ultrafiltrate concentrates and obtains the extractum that relative density is 1.35～1.39 (55 ℃).The operating condition of ultrafiltration technology is: the inlet pressure of ultrafiltration is 0.35Mpa, and the liquid outlet pressure ratio inlet pressure of ultrafiltration hangs down 0.20kPa.The ultrafiltration initial stage is adopted lower pressure, slowly boosts then; In ultra-filtration process, adopt the periodic pressure fluctuation, the pressure wave moment is 0.2Mpa.The feed liquid flow velocity is 3.0m/s, in the ultra-filtration process, adopts periodically flow fluctuation so that produce pulsating flow or non-stationary flow in membrane channels, the flow speed wave moment is 2.0m/s, feeds nitrogen in the ultrafiltration system discontinuous, forms the gas-liquid stream of pulses, cycle is that 2h ventilates once each 1 minute.Feed temperature is 40 ℃, when feed liquid stock solution is concentrated 1/8, adds the water ultrafiltration again 2 times, and the pH value of feed liquid is controlled at 7.5.
Get that above-mentioned extractum and adjuvant sucrose ester and glyceryl monostearate are mixed evenly to be heated to 60 ℃ of temperature, change material after 30 minutes, move in the dropping-pill machine jar that jar temperature remains on 90 ℃.In medicine liquid droplet to the 6 ℃ liquid paraffin, take out drop pill, oil removing, screen cloth selects ball, promptly.The result shows, prepared drop pill rounding, even, consistent, the no adhesion phenomenon of color and luster of size.By measuring under Chinese Pharmacopoeia version in 2000 the method disintegration item, the result does not add the average 2.67min of baffle plate by screen cloth, meets the pharmacopeia regulation this disintegration.
Embodiment 13
Crude drug Radix Salviae Miltiorrhizae 47.0g, Radix Notoginseng 8.6g, Fructus Aurantii 2g, Borneolum Syntheticum 0.40g; Adjuvant sucrose ester 10.0g, polyoxyethylene monostearate 2.0g, cross-linking sodium carboxymethyl cellulose 3.0g.
Radix Salviae Miltiorrhizae, pseudo-ginseng and the Fructus Aurantii medical material of coarse pulverization to extraction pot, added 5 times of water gagings, decocted 2 hours, filter, filtering residue carries out second time and extracts, and adds 4 times of water gagings, fried in shallow oil 1 hour, and filtration, filtering residue discards, merging filtrate.Filtrate is that 60000 polysulfone membrane is carried out ultrafiltration with molecular cut off, and ultrafiltrate concentrates and obtains the extractum that relative density is 1.35～1.39 (55 ℃).The operating condition of ultrafiltration technology is: the inlet pressure of ultrafiltration is 0.1Mpa, and the liquid outlet pressure ratio inlet pressure of ultrafiltration hangs down 0.5kPa.The ultrafiltration initial stage is adopted lower pressure, slowly boosts then; In ultra-filtration process, adopt the periodic pressure fluctuation, the pressure wave moment is 0.1Mpa.The feed liquid flow velocity is 1.0m/s, in the ultra-filtration process, adopts periodically flow fluctuation so that produce pulsating flow or non-stationary flow in membrane channels, the flow speed wave moment is 1.0m/s, feeds nitrogen in the ultrafiltration system discontinuous, forms the gas-liquid stream of pulses, cycle is that 0.5h ventilates once each 1 minute.Feed temperature is 15 ℃, when feed liquid stock solution is concentrated 1/15, adds the water ultrafiltration again 1 time, and the pH value of feed liquid is controlled at 5.
Get above-mentioned extractum and Borneolum Syntheticum, evenly be heated to 65 ℃ of temperature, change material after 30 minutes, move in the dropping-pill machine jar that jar temperature remains on 90 ℃ with adjuvant sucrose ester, polyoxyethylene monostearate and cross-linking sodium carboxymethyl cellulose are mixed.In medicine liquid droplet to the 4 ℃ methyl-silicone oil, take out drop pill, oil removing, screen cloth selects ball, promptly.The result shows, prepared drop pill rounding, even, consistent, the no adhesion phenomenon of color and luster of size.By measuring under Chinese Pharmacopoeia version in 2000 the method disintegration item, the result does not add the average 2.66min of baffle plate by screen cloth, meets the pharmacopeia regulation this disintegration.
Embodiment 14
Crude drug Radix Salviae Miltiorrhizae 97.0g, Radix Notoginseng 79.0g, Fructus Aurantii 35g, Radix Codonopsis 40g; Adjuvant lactose 40.0g, carrageenan 18.0g, starch 15.0g.
Learn from else's experience Radix Salviae Miltiorrhizae, Radix Notoginseng, Fructus Aurantii and the codonopsis pilosula of coarse pulverization to extraction pot, add the 0.89g sodium bicarbonate, add 4 times of water gagings, decocted 2 hours, filter, filtering residue carries out extraction second time, adds 4 times of water gagings, decocted 1 hour, and filtration, filtering residue discards, merging filtrate.Filtrate is that 50000 polysulfonamides film carries out ultrafiltration with molecular cut off, and ultrafiltrate concentrates and obtains the extractum that relative density is 1.35～1.39 (55 ℃).The operating condition of ultrafiltration technology is: the inlet pressure of ultrafiltration is 0.5Mpa, and the liquid outlet pressure ratio inlet pressure of ultrafiltration hangs down 0.25kPa.The ultrafiltration initial stage is adopted lower pressure, slowly boosts then; In ultra-filtration process, adopt the periodic pressure fluctuation, the pressure wave moment is 0.2Mpa.The feed liquid flow velocity is 4.0m/s, in the ultra-filtration process, adopts periodically flow fluctuation so that produce pulsating flow or non-stationary flow in membrane channels, the flow speed wave moment is 2.0m/s, feeds nitrogen in the ultrafiltration system discontinuous, forms the gas-liquid stream of pulses, cycle is that 2h ventilates once each 1 minute.Feed temperature is 50 ℃, when feed liquid stock solution is concentrated 1/5, adds the dilute alcohol solution ultrafiltration again 2 times, and the pH value of feed liquid is controlled at 9.
Get that above-mentioned extractum and adjuvant lactose, carrageenan and starch are mixed evenly to be heated to 60 ℃ of temperature, change material after 30 minutes, move in the dropping-pill machine jar that jar temperature remains on 90 ℃.In medicine liquid droplet to the 5 ℃ liquid paraffin, take out drop pill, oil removing, screen cloth selects ball, promptly.The result shows, prepared drop pill rounding, even, consistent, the no adhesion phenomenon of color and luster of size.By measuring under Chinese Pharmacopoeia version in 2000 the method disintegration item, the result does not add the average 2.77min of baffle plate by screen cloth, meets the pharmacopeia regulation this disintegration.
Embodiment 15
Crude drug Radix Salviae Miltiorrhizae 20.0g, Radix Notoginseng 2.0, Fructus Aurantii 3.0g, Borneolum Syntheticum 0.2g, Radix Ginseng 10.0g; Adjuvant xylitol 5.0g, lactose 2.0g, arabic gum 2.0g.
Radix Salviae Miltiorrhizae, Radix Notoginseng, Fructus Aurantii and the ginseng crude drug of coarse pulverization to extraction pot, added 5 times of water gagings, decocted 2 hours, filter, filtering residue carries out second time and extracts, and adds 4 times of water gagings, fried in shallow oil 1 hour, and filtration, filtering residue discards, merging filtrate.Filtrate decompression is concentrated into medicine liquid volume (L) and medical material weight (Kg) than being 1: 0.9～1.1, adds ethanol and makes medicinal liquid contain determining alcohol 75%, leaves standstill filtration.Filtrate is that 20000 polysulfone membrane is carried out ultrafiltration with molecular cut off, and ultrafiltrate concentrates and obtains the extractum that relative density is 1.35～1.39 (55 ℃).The ultrafiltration initial stage is adopted lower pressure, slowly boosts then; In ultra-filtration process, adopt the periodic pressure fluctuation, the pressure wave moment is 0.1Mpa.The feed liquid flow velocity is 1.0m/s, in the ultra-filtration process, adopts periodically flow fluctuation so that produce pulsating flow or non-stationary flow in membrane channels, the flow speed wave moment is 1.0m/s, feeds nitrogen in the ultrafiltration system discontinuous, forms the gas-liquid stream of pulses, cycle is that 0.5h ventilates once each 1 minute.Feed temperature is 15 ℃, when feed liquid stock solution is concentrated 1/15, adds the water ultrafiltration again 1 time, and the pH value of feed liquid is controlled at 6.
Get above-mentioned extractum and Borneolum Syntheticum, evenly be heated to 60 ℃ of temperature, change material after 30 minutes, move in the dropping-pill machine jar that jar temperature remains on 84 ℃ with adjuvant xylitol, lactose and arabic gum are mixed.In medicine liquid droplet to the 7 ℃ liquid paraffin, take out drop pill, oil removing, screen cloth selects ball, promptly.The result shows, prepared drop pill rounding, even, consistent, the no adhesion phenomenon of color and luster of size.By measuring under Chinese Pharmacopoeia version in 2000 the method disintegration item, the result does not add the average 2.55min of baffle plate by screen cloth, meets the pharmacopeia regulation this disintegration.
Embodiment 16
Crude drug Radix Salviae Miltiorrhizae 18.0g, Radix Notoginseng 20.0g, Fructus Aurantii 15.5g, Borneolum Syntheticum 0.26g, Herba Leonuri 7.5g; Adjuvant sucrose ester 10.0g, polyoxyethylene monostearate 6.0g, cross-linking sodium carboxymethyl cellulose 1.0g, silica 1 .0g.
Radix Salviae Miltiorrhizae, Radix Notoginseng, Fructus Aurantii and the Herba Leonuri medical material of coarse pulverization to extraction pot, added 5 times of water gagings, decocted 2 hours, filter, filtering residue carries out second time and extracts, and adds 4 times of water gagings, fried in shallow oil 1 hour, and filtration, filtering residue discards, merging filtrate.Filtrate decompression is concentrated into medicine liquid volume (L) and medical material weight (Kg) than being 1: 0.9～1.1, adds ethanol and makes medicinal liquid contain determining alcohol 70%, leaves standstill filtration.Filtrate is that 20000 polysulfone membrane is carried out ultrafiltration with molecular cut off, and ultrafiltrate concentrates and obtains the extractum that relative density is 1.35～1.39 (55 ℃).The ultrafiltration initial stage is adopted lower pressure, slowly boosts then; In ultra-filtration process, adopt the periodic pressure fluctuation, the pressure wave moment is 0.1Mpa.The feed liquid flow velocity is 1.0m/s, in the ultra-filtration process, adopts periodically flow fluctuation so that produce pulsating flow or non-stationary flow in membrane channels, the flow speed wave moment is 1.0m/s, feeds nitrogen in the ultrafiltration system discontinuous, forms the gas-liquid stream of pulses, cycle is that 0.5h ventilates once each 1 minute.Feed temperature is 15 ℃, when feed liquid stock solution is concentrated 1/15, adds the dilute alcohol solution ultrafiltration again 1 time, and the pH value of feed liquid is controlled at 6.
Get above-mentioned extractum and Borneolum Syntheticum,, mixed evenly be heated to 60 ℃ of temperature, change material after 30 minutes, move in the dropping-pill machine jar that jar temperature remains on 84 ℃ with adjuvant sucrose ester, polyoxyethylene monostearate, cross-linking sodium carboxymethyl cellulose and silicon dioxide.In medicine liquid droplet to the 7 ℃ liquid paraffin, take out drop pill, oil removing, screen cloth selects ball, promptly.The result shows, prepared drop pill rounding, even, consistent, the no adhesion phenomenon of color and luster of size.By measuring under Chinese Pharmacopoeia version in 2000 the method disintegration item, the result does not add the average 2.57min of baffle plate by screen cloth, meets the pharmacopeia regulation this disintegration.
Embodiment 17
Crude drug Radix Salviae Miltiorrhizae 23.0g, Radix Notoginseng 7.8g, Fructus Aurantii 35g, Lignum Dalbergiae Odoriferae oil 0.21g, Radix Astragali 27.0g; Adjuvant lactose 14.0g, tragakanta 5.0g.
Learn from else's experience Radix Salviae Miltiorrhizae, Radix Notoginseng, Fructus Aurantii and the Milkvetch Root of coarse pulverization to extraction pot, add the 0.88g sodium bicarbonate, add 4 times of water gagings, decocted 2 hours, filter, filtering residue carries out extraction second time, adds 4 times of water gagings, decocted 1 hour, and filtration, filtering residue discards, merging filtrate.Filtrate decompression is concentrated into medicine liquid volume (L) and medical material weight (Kg) than being 1: 0.9～1.1, adds ethanol and makes medicinal liquid contain determining alcohol 70%, leaves standstill filtration.Filtrate is that 20000 polyvinylidene fluoride film carries out ultrafiltration with molecular cut off, and ultrafiltrate concentrates and obtains the extractum that relative density is 1.35～1.39 (55 ℃).The operating condition of ultrafiltration technology is: the inlet pressure of ultrafiltration is 0.35Mpa, and the liquid outlet pressure ratio inlet pressure of ultrafiltration hangs down 0.20kPa.The ultrafiltration initial stage is adopted lower pressure, slowly boosts then; In ultra-filtration process, adopt the periodic pressure fluctuation, the pressure wave moment is 0.2Mpa.The feed liquid flow velocity is 3.0m/s, in the ultra-filtration process, adopts periodically flow fluctuation so that produce pulsating flow or non-stationary flow in membrane channels, the flow speed wave moment is 2.0m/s, feeds nitrogen in the ultrafiltration system discontinuous, forms the gas-liquid stream of pulses, cycle is that 2h ventilates once each 1 minute.Feed temperature is 40 ℃, when feed liquid stock solution is concentrated 1/9, adds the water ultrafiltration again 2 times, and the pH value of feed liquid is controlled at 7.5.
Get above-mentioned extractum and Lignum Dalbergiae Odoriferae oil, evenly mixed with adjuvant lactose and tragakanta, be heated to 65 ℃ of temperature, change material after 30 minutes, move in the dropping-pill machine jar that jar temperature remains on 85 ℃.In medicine liquid droplet to the 8 ℃ liquid paraffin, take out drop pill, oil removing, screen cloth selects ball, promptly.The result shows, prepared drop pill rounding, even, consistent, the no adhesion phenomenon of color and luster of size.By measuring under Chinese Pharmacopoeia version in 2000 the method disintegration item, the result does not add the average 2.49min of baffle plate by screen cloth, meets the pharmacopeia regulation this disintegration.
Embodiment 18
Crude drug Radix Salviae Miltiorrhizae 24.2g, Radix Notoginseng 25.0g, Fructus Aurantii 5g, Radix Codonopsis 10.0g; Adjuvant lactose 18.0 g, pregelatinized Starch 4.5g.
Radix Salviae Miltiorrhizae, Radix Notoginseng, Fructus Aurantii and the codonopsis pilosula of coarse pulverization to extraction pot, added 5 times of water gagings, decocted 2 hours, filter, filtering residue carries out second time and extracts, and adds 4 times of water gagings, fried in shallow oil 1 hour, and filtration, filtering residue discards, merging filtrate.Filtrate decompression is concentrated into medicine liquid volume (L) and medical material weight (Kg) than being 1: 0.9～1.1, adds ethanol and makes medicinal liquid contain determining alcohol 70%, leaves standstill, and filters, and filtrate is concentrated to obtain the extractum that relative density is 1.32～1.40 (55 ℃).
Get that above-mentioned extractum and adjuvant lactose and pregelatinized Starch are mixed evenly to be heated to 60 ℃ of temperature, change material after 30 minutes, move in the dropping-pill machine jar that jar temperature remains on 90 ℃.In medicine liquid droplet to the 7 ℃ liquid paraffin, take out drop pill, oil removing, screen cloth selects ball, promptly.The result shows, prepared drop pill rounding, even, consistent, the no adhesion phenomenon of color and luster of size.By measuring under Chinese Pharmacopoeia version in 2000 the method disintegration item, the result does not add the average 2.81min of baffle plate by screen cloth, meets the pharmacopeia regulation this disintegration.
Embodiment 19
Crude drug Radix Salviae Miltiorrhizae 26.2g, Radix Notoginseng 7.0g, Fructus Aurantii 6g, Radix Angelicae Sinensis 10.8g; Adjuvant xylitol 15.0g, starch 5.0g.
Learn from else's experience Radix Salviae Miltiorrhizae, Radix Notoginseng, Fructus Aurantii and the Radix Angelicae Sinensis medical material of coarse pulverization to extraction pot, add the 0.9g sodium bicarbonate, add 4 times of water gagings, decocted 2 hours, filter, filtering residue carries out extraction second time, adds 4 times of water gagings, decocted 1 hour, and filtration, filtering residue discards, merging filtrate.Filtrate decompression is concentrated into medicine liquid volume (L) and medical material weight (Kg) than being 1: 0.9～1.1, adds ethanol and makes medicinal liquid contain determining alcohol 75%, leaves standstill, and filters, and filtrate is concentrated to obtain the extractum that relative density is 1.32～1.40 (55 ℃).
Get that above-mentioned extractum and adjuvant xylitol and starch are mixed evenly to be heated to 65 ℃ of temperature, change material after 30 minutes, move in the dropping-pill machine jar that jar temperature remains on 85 ℃.In medicine liquid droplet to the 8 ℃ liquid paraffin, take out drop pill, oil removing, screen cloth selects ball, promptly.The result shows, prepared drop pill rounding, even, consistent, the no adhesion phenomenon of color and luster of size.By measuring under Chinese Pharmacopoeia version in 2000 the method disintegration item, the result does not add the average 2.73min of baffle plate by screen cloth, meets the pharmacopeia regulation this disintegration.
Embodiment 20
Crude drug Radix Salviae Miltiorrhizae 30.8g, Radix Notoginseng 15.2g, Fructus Aurantii 16.2g, Lignum Dalbergiae Odoriferae oil 0.25g, Herba Leonuri 8.0g; Adjuvant lactose 18.0g, arabic gum 4.0g.
With ethanol extraction Radix Salviae Miltiorrhizae, Radix Notoginseng, Fructus Aurantii and Herba Leonuri medical material, obtain Radix Salviae Miltiorrhizae, Radix Notoginseng, Fructus Aurantii and Herba Leonuri ethanol extract, with this extracting liquid filtering, collect filtrate with gauze.Filtrate is that 20000 cellulose diacetate film carries out ultrafiltration with molecular cut off, and ultrafiltrate concentrates and obtains the extractum that relative density is 1.35～1.39 (55 ℃).The condition of above-mentioned ultrafiltration is: the inlet pressure of ultrafiltration is 0.35Mpa, and the liquid outlet pressure ratio inlet pressure of ultrafiltration hangs down 0.20kPa.The ultrafiltration initial stage is adopted lower pressure, slowly boosts then; In ultra-filtration process, adopt the periodic pressure fluctuation, the pressure wave moment is 0.2Mpa.The feed liquid flow velocity is 3.0m/s, in the ultra-filtration process, adopts periodically flow fluctuation so that produce pulsating flow or non-stationary flow in membrane channels, the flow speed wave moment is 2.0m/s, feeds nitrogen in the ultrafiltration system discontinuous, forms the gas-liquid stream of pulses, cycle is that 2h ventilates once each 1 minute.Feed temperature is 40 ℃, when feed liquid stock solution is concentrated 1/8, adds the dilute alcohol solution ultrafiltration again 2 times, and the pH value of feed liquid is controlled at 7.5.
Get above-mentioned extractum and Lignum Dalbergiae Odoriferae oil, evenly mixed with adjuvant lactose and arabic gum, be heated to 60 ℃ of temperature, change material after 30 minutes, move in the dropping-pill machine jar that jar temperature remains on 85 ℃.In medicine liquid droplet to the 6 ℃ liquid paraffin, take out drop pill, oil removing, screen cloth selects ball, promptly.The result shows, prepared drop pill rounding, even, consistent, the no adhesion phenomenon of color and luster of size.By measuring under Chinese Pharmacopoeia version in 2000 the method disintegration item, the result does not add the average 2.60min of baffle plate by screen cloth, meets the pharmacopeia regulation this disintegration.
Embodiment 21
Crude drug Radix Salviae Miltiorrhizae 48.5g, Radix Notoginseng 39.5g, Fructus Aurantii 17.5; Adjuvant xylitol 26.0g, tragakanta 8.0g.
The Radix Salviae Miltiorrhizae and the Radix Notoginseng of coarse pulverization are added 5 times of water gagings, decocted 2 hours, filter, filtering residue carries out the second time and extracts, and adds 4 times of water gagings, fries in shallow oil 1 hour, filters, and filtering residue discards, and merging filtrate gets Radix Salviae Miltiorrhizae and Radix Ginseng extractive solution, leaves standstill, and filters.Filtrate is that 60000 polysulfone membrane is carried out ultrafiltration with molecular cut off, and ultrafiltrate concentrates and obtains the extractum that relative density is 1.35～1.39 (55 ℃).The operating condition of ultrafiltration technology is: the inlet pressure of ultrafiltration is 0.35Mpa, and the liquid outlet pressure ratio inlet pressure of ultrafiltration hangs down 0.20kPa.The ultrafiltration initial stage is adopted lower pressure, slowly boosts then; In ultra-filtration process, adopt the periodic pressure fluctuation, the pressure wave moment is 0.2Mpa.The feed liquid flow velocity is 3.0m/s, in the ultra-filtration process, adopts periodically flow fluctuation so that produce pulsating flow or non-stationary flow in membrane channels, the flow speed wave moment is 2.0m/s, feeds nitrogen in the ultrafiltration system discontinuous, forms the gas-liquid stream of pulses, cycle is that 2h ventilates once each 1 minute.Feed temperature is 40 ℃, when feed liquid stock solution is concentrated 1/8, adds the water ultrafiltration again 2 times, and the pH value of feed liquid is controlled at 7.5.
Get that above-mentioned extractum and adjuvant xylitol and tragakanta are mixed evenly to be heated to 60 ℃ of temperature, change material after 25 minutes, move in the dropping-pill machine jar that jar temperature remains on 89 ℃.In medicine liquid droplet to the 5 ℃ liquid paraffin, take out drop pill, oil removing, screen cloth selects ball, promptly.The result shows, prepared drop pill rounding, even, consistent, the no adhesion phenomenon of color and luster of size.By measuring under Chinese Pharmacopoeia version in 2000 the method disintegration item, the result does not add the average 2.59min of baffle plate by screen cloth, meets the pharmacopeia regulation this disintegration.
Embodiment 22
Crude drug Radix Salviae Miltiorrhizae 26.0g, Radix Notoginseng 3.0g, Fructus Aurantii 12g, Borneolum Syntheticum 0.21g, Radix Angelicae Sinensis 10.0g; Adjuvant sucrose ester 13.0g, polyoxyethylene monostearate 8.0g.
With 80% ethanol extraction Radix Salviae Miltiorrhizae and Radix Angelicae Sinensis, obtain Radix Salviae Miltiorrhizae and Radix Angelicae Sinensis ethanol extract, get supernatant with dividing behind this extracting solution high speed centrifugation.With this liquid molecular cut off is that 50000 sulfonated polysulfone membrane carries out ultrafiltration, and ultrafiltrate concentrates and obtains the extractum that relative density is 1.35～1.39 (55 ℃).The operating condition of ultrafiltration technology is: the inlet pressure of ultrafiltration is 0.5Mpa, and the liquid outlet pressure ratio inlet pressure of ultrafiltration hangs down 0.25kPa.The ultrafiltration initial stage is adopted lower pressure, slowly boosts then; In ultra-filtration process, adopt the periodic pressure fluctuation, the pressure wave moment is 0.2Mpa.The feed liquid flow velocity is 4.0m/s, in the ultra-filtration process, adopts periodically flow fluctuation so that produce pulsating flow or non-stationary flow in membrane channels, the flow speed wave moment is 2.0m/s, feeds nitrogen in the ultrafiltration system discontinuous, forms the gas-liquid stream of pulses, cycle is that 2h ventilates once each 1 minute.Feed temperature is 50 ℃, when feed liquid stock solution is concentrated 1/5, adds the dilute alcohol solution ultrafiltration again 2 times, and the pH value of feed liquid is controlled at 9.
Get above-mentioned extractum and Borneolum Syntheticum, evenly mixed with adjuvant sucrose ester and polyoxyethylene monostearate, be heated to 60 ℃ of temperature, change material after 30 minutes, move in the dropping-pill machine jar that jar temperature remains on 90 ℃.In medicine liquid droplet to the 5 ℃ liquid paraffin, take out drop pill, oil removing, screen cloth selects ball, promptly.The result shows, prepared drop pill rounding, even, consistent, the no adhesion phenomenon of color and luster of size.By measuring under Chinese Pharmacopoeia version in 2000 the method disintegration item, the result does not add the average 2.61min of baffle plate by screen cloth, meets the pharmacopeia regulation this disintegration.
Embodiment 23
Crude drug Radix Salviae Miltiorrhizae 49.0g, Radix Notoginseng 12.5g, Fructus Aurantii 3g, Borneolum Syntheticum 0.20g, Radix Ginseng 6.0g; Adjuvant sucrose ester 15.0g, glyceryl monostearate 4.0g.
Radix Salviae Miltiorrhizae, Radix Notoginseng, Fructus Aurantii and the ginseng crude drug of coarse pulverization to extraction pot, added 5 times of water gagings, decocted 2 hours, filter, filtering residue carries out second time and extracts, and adds 4 times of water gagings, fried in shallow oil 1 hour, and filtration, filtering residue discards, merging filtrate.Filtrate is that 60000 poly (ether sulfone) film carries out ultrafiltration with molecular cut off, and ultrafiltrate concentrates and obtains the extractum that relative density is 1.35～1.39 (55 ℃).The operating condition of ultrafiltration technology is: the inlet pressure of ultrafiltration is 0.35Mpa, and the liquid outlet pressure ratio inlet pressure of ultrafiltration hangs down 0.20kPa.The ultrafiltration initial stage is adopted lower pressure, slowly boosts then; In ultra-filtration process, adopt the periodic pressure fluctuation, the pressure wave moment is 0.2Mpa.The feed liquid flow velocity is 3.0m/s, in the ultra-filtration process, adopts periodically flow fluctuation so that produce pulsating flow or non-stationary flow in membrane channels, the flow speed wave moment is 2.0m/s, feeds nitrogen in the ultrafiltration system discontinuous, forms the gas-liquid stream of pulses, cycle is that 2h ventilates once each 1 minute.Feed temperature is 40 ℃, when feed liquid stock solution is concentrated 1/8, adds the water ultrafiltration again 2 times, and the pH value of feed liquid is controlled at 7.5.
Get above-mentioned extractum and Borneolum Syntheticum, evenly mixed with adjuvant sucrose ester and glyceryl monostearate, be heated to 60 ℃ of temperature, change material after 30 minutes, move in the dropping-pill machine jar that jar temperature remains on 90 ℃.In medicine liquid droplet to the 6 ℃ liquid paraffin, take out drop pill, oil removing, screen cloth selects ball, promptly.The result shows, prepared drop pill rounding, even, consistent, the no adhesion phenomenon of color and luster of size.By measuring under Chinese Pharmacopoeia version in 2000 the method disintegration item, the result does not add the average 2.62min of baffle plate by screen cloth, meets the pharmacopeia regulation this disintegration.
Embodiment 24
Crude drug Radix Salviae Miltiorrhizae 21.0g, Radix Notoginseng 8.5g, Fructus Aurantii 13.5g, Styrax 0.20g, Radix Angelicae Sinensis 9.0g; Adjuvant sucrose ester 13.0g, polyoxyethylene monostearate 2.0g, cross-linking sodium carboxymethyl cellulose 3.0g.
Radix Salviae Miltiorrhizae, Radix Notoginseng, Fructus Aurantii and the Radix Angelicae Sinensis medical material of coarse pulverization to extraction pot, added 5 times of water gagings, decocted 2 hours, filter, filtering residue carries out second time and extracts, and adds 4 times of water gagings, fried in shallow oil 1 hour, and filtration, filtering residue discards, merging filtrate.Filtrate is that 60000 polysulfone membrane is carried out ultrafiltration with molecular cut off, and ultrafiltrate concentrates and obtains the extractum that relative density is 1.35～1.39 (55 ℃).The operating condition of ultrafiltration technology is: the inlet pressure of ultrafiltration is 0.1Mpa, and the liquid outlet pressure ratio inlet pressure of ultrafiltration hangs down 0.5kPa.The ultrafiltration initial stage is adopted lower pressure, slowly boosts then; In ultra-filtration process, adopt the periodic pressure fluctuation, the pressure wave moment is 0.1Mpa.The feed liquid flow velocity is 1.0m/s, in the ultra-filtration process, adopts periodically flow fluctuation so that produce pulsating flow or non-stationary flow in membrane channels, the flow speed wave moment is 1.0m/s, feeds nitrogen in the ultrafiltration system discontinuous, forms the gas-liquid stream of pulses, cycle is that 0.5h ventilates once each 1 minute.Feed temperature is 15 ℃, when feed liquid stock solution is concentrated 1/15, adds the water ultrafiltration again 1 time, and the pH value of feed liquid is controlled at 5.
Get above-mentioned extractum and Styrax, evenly be heated to 65 ℃ of temperature, change material after 30 minutes, move in the dropping-pill machine jar that jar temperature remains on 90 ℃ with adjuvant sucrose ester, polyoxyethylene monostearate and cross-linking sodium carboxymethyl cellulose are mixed.In medicine liquid droplet to the 4 ℃ methyl-silicone oil, take out drop pill, oil removing, screen cloth selects ball, promptly.The result shows, prepared drop pill rounding, even, consistent, the no adhesion phenomenon of color and luster of size.By measuring under Chinese Pharmacopoeia version in 2000 the method disintegration item, the result does not add the average 2.62min of baffle plate by screen cloth, meets the pharmacopeia regulation this disintegration.
Embodiment 25
Crude drug Radix Salviae Miltiorrhizae 31.0g, Radix Notoginseng 31.5g, Fructus Aurantii 45g, muscone 0.18g, Radix Codonopsis 12.5g; Adjuvant lactose 18.0g, carrageenan 8.0g, starch 2.0g.
Learn from else's experience Radix Salviae Miltiorrhizae, Radix Notoginseng, Fructus Aurantii and the codonopsis pilosula of coarse pulverization to extraction pot, add the 0.89g sodium bicarbonate, add 4 times of water gagings, decocted 2 hours, filter, filtering residue carries out extraction second time, adds 4 times of water gagings, decocted 1 hour, and filtration, filtering residue discards, merging filtrate.Filtrate is that 50000 polysulfonamides film carries out ultrafiltration with molecular cut off, and ultrafiltrate concentrates and obtains the extractum that relative density is 1.35～1.39 (55 ℃).The operating condition of ultrafiltration technology is: the inlet pressure of ultrafiltration is 0.5Mpa, and the liquid outlet pressure ratio inlet pressure of ultrafiltration hangs down 0.25kPa.The ultrafiltration initial stage is adopted lower pressure, slowly boosts then; In ultra-filtration process, adopt the periodic pressure fluctuation, the pressure wave moment is 0.2Mpa.The feed liquid flow velocity is 4.0m/s, in the ultra-filtration process, adopts periodically flow fluctuation so that produce pulsating flow or non-stationary flow in membrane channels, the flow speed wave moment is 2.0m/s, feeds nitrogen in the ultrafiltration system discontinuous, forms the gas-liquid stream of pulses, cycle is that 2h ventilates once each 1 minute.Feed temperature is 50 ℃, when feed liquid stock solution is concentrated 1/5, adds the dilute alcohol solution ultrafiltration again 2 times, and the pH value of feed liquid is controlled at 9.
Get above-mentioned extractum and muscone, evenly be heated to 60 ℃ of temperature, change material after 30 minutes, move in the dropping-pill machine jar that jar temperature remains on 90 ℃ with adjuvant lactose, carrageenan and starch are mixed.In medicine liquid droplet to the 5 ℃ liquid paraffin, take out drop pill, oil removing, screen cloth selects ball, promptly.The result shows, prepared drop pill rounding, even, consistent, the no adhesion phenomenon of color and luster of size.By measuring under Chinese Pharmacopoeia version in 2000 the method disintegration item, the result does not add the average 2.74min of baffle plate by screen cloth, meets the pharmacopeia regulation this disintegration.
Embodiment 26
Crude drug Radix Salviae Miltiorrhizae 28.0g, Radix Notoginseng 16.6g, Fructus Aurantii 9.5g, Lignum Dalbergiae Odoriferae oil 0.20g, Radix Angelicae Sinensis 8.0g; Adjuvant xylitol 10.0g, lactose 3.0g, arabic gum 5.0g.
Radix Salviae Miltiorrhizae, Radix Notoginseng, Fructus Aurantii and the Radix Angelicae Sinensis medical material of coarse pulverization to extraction pot, added 5 times of water gagings, decocted 2 hours, filter, filtering residue carries out second time and extracts, and adds 4 times of water gagings, fried in shallow oil 1 hour, and filtration, filtering residue discards, merging filtrate.Filtrate decompression is concentrated into medicine liquid volume (L) and medical material weight (Kg) than being 1: 0.9～1.1, adds ethanol and makes medicinal liquid contain determining alcohol 75%, leaves standstill filtration.Filtrate is that 20000 polysulfone membrane is carried out ultrafiltration with molecular cut off, and ultrafiltrate concentrates and obtains the extractum that relative density is 1.35～1.39 (55 ℃).The ultrafiltration initial stage is adopted lower pressure, slowly boosts then; In ultra-filtration process, adopt the periodic pressure fluctuation, the pressure wave moment is 0.1Mpa.The feed liquid flow velocity is 1.0m/s, in the ultra-filtration process, adopts periodically flow fluctuation so that produce pulsating flow or non-stationary flow in membrane channels, the flow speed wave moment is 1.0m/s, feeds nitrogen in the ultrafiltration system discontinuous, forms the gas-liquid stream of pulses, cycle is that 0.5h ventilates once each 1 minute.Feed temperature is 15 ℃, when feed liquid stock solution is concentrated 1/15, adds the dilute alcohol solution ultrafiltration again 1 time, and the pH value of feed liquid is controlled at 6.
Get above-mentioned extractum and Lignum Dalbergiae Odoriferae oil, evenly be heated to 60 ℃ of temperature, change material after 30 minutes, move in the dropping-pill machine jar that jar temperature remains on 84 ℃ with adjuvant xylitol, lactose and arabic gum are mixed.In medicine liquid droplet to the 7 ℃ liquid paraffin, take out drop pill, oil removing, screen cloth selects ball, promptly.The result shows, prepared drop pill rounding, even, consistent, the no adhesion phenomenon of color and luster of size.By measuring under Chinese Pharmacopoeia version in 2000 the method disintegration item, the result does not add the average 2.57min of baffle plate by screen cloth, meets the pharmacopeia regulation this disintegration.
Embodiment 27
Crude drug Radix Salviae Miltiorrhizae 28.0g, Radix Notoginseng 18.0g, Fructus Aurantii 14.5g, Moschus 0.21g, Radix Ginseng 18.7g; Adjuvant sucrose ester 14.0g, polyoxyethylene monostearate 6.0g, cross-linking sodium carboxymethyl cellulose 1.0g, silica 1 .0g.
Radix Salviae Miltiorrhizae, Radix Notoginseng, Fructus Aurantii and the ginseng crude drug of coarse pulverization to extraction pot, added 5 times of water gagings, decocted 2 hours, filter, filtering residue carries out second time and extracts, and adds 4 times of water gagings, fried in shallow oil 1 hour, and filtration, filtering residue discards, merging filtrate.Filtrate decompression is concentrated into medicine liquid volume (L) and medical material weight (Kg) than being 1: 0.9～1.1, adds ethanol and makes medicinal liquid contain determining alcohol 70%, leaves standstill filtration.Filtrate is that 20000 polysulfone membrane is carried out ultrafiltration with molecular cut off, and ultrafiltrate concentrates and obtains the extractum that relative density is 1.35～1.39 (55 ℃).The ultrafiltration initial stage is adopted lower pressure, slowly boosts then; In ultra-filtration process, adopt the periodic pressure fluctuation, the pressure wave moment is 0.1Mpa.The feed liquid flow velocity is 1.0m/s, in the ultra-filtration process, adopts periodically flow fluctuation so that produce pulsating flow or non-stationary flow in membrane channels, the flow speed wave moment is 1.0m/s, feeds nitrogen in the ultrafiltration system discontinuous, forms the gas-liquid stream of pulses, cycle is that 0.5h ventilates once each 1 minute.Feed temperature is 15 ℃, when feed liquid stock solution is concentrated 1/15, adds the dilute alcohol solution ultrafiltration again 1 time, and the pH value of feed liquid is controlled at 6.
Get above-mentioned extractum and Moschus,, mixed evenly be heated to 60 ℃ of temperature, change material after 30 minutes, move in the dropping-pill machine jar that jar temperature remains on 84 ℃ with adjuvant sucrose ester, polyoxyethylene monostearate, cross-linking sodium carboxymethyl cellulose and silicon dioxide.In medicine liquid droplet to the 7 ℃ liquid paraffin, take out drop pill, oil removing, screen cloth selects ball, promptly.The result shows, prepared drop pill rounding, even, consistent, the no adhesion phenomenon of color and luster of size.By measuring under Chinese Pharmacopoeia version in 2000 the method disintegration item, the result does not add the average 2.62min of baffle plate by screen cloth, meets the pharmacopeia regulation this disintegration.
Embodiment 28
Crude drug Radix Salviae Miltiorrhizae 23.0g, Radix Notoginseng 7.8g, Fructus Aurantii 22g, Radix Ginseng 15.0g; Adjuvant lactose 18.0g, tragakanta 5.0g.
Learn from else's experience Radix Salviae Miltiorrhizae, Radix Notoginseng, Fructus Aurantii and the ginseng crude drug of coarse pulverization to extraction pot, add the 0.88g sodium bicarbonate, add 4 times of water gagings, decocted 2 hours, filter, filtering residue carries out extraction second time, adds 4 times of water gagings, decocted 1 hour, and filtration, filtering residue discards, merging filtrate.Filtrate decompression is concentrated into medicine liquid volume (L) and medical material weight (Kg) than being 1: 0.9～1.1, adds ethanol and makes medicinal liquid contain determining alcohol 70%, leaves standstill filtration.Filtrate is that 20000 polyvinylidene fluoride film carries out ultrafiltration with molecular cut off, and ultrafiltrate concentrates and obtains the extractum that relative density is 1.35～1.39 (55 ℃).The operating condition of ultrafiltration technology is: the inlet pressure of ultrafiltration is 0.35Mpa, and the liquid outlet pressure ratio inlet pressure of ultrafiltration hangs down 0.20kPa.The ultrafiltration initial stage is adopted lower pressure, slowly boosts then; In ultra-filtration process, adopt the periodic pressure fluctuation, the pressure wave moment is 0.2Mpa.The feed liquid flow velocity is 3.0m/s, in the ultra-filtration process, adopts periodically flow fluctuation so that produce pulsating flow or non-stationary flow in membrane channels, the flow speed wave moment is 2.0m/s, feeds nitrogen in the ultrafiltration system discontinuous, forms the gas-liquid stream of pulses, cycle is that 2h ventilates once each 1 minute.Feed temperature is 40 ℃, when feed liquid stock solution is concentrated 1/9, adds the water ultrafiltration again 2 times, and the pH value of feed liquid is controlled at 7.5.
Get that above-mentioned extractum and adjuvant lactose and tragakanta are mixed evenly to be heated to 65 ℃ of temperature, change material after 30 minutes, move in the dropping-pill machine jar that jar temperature remains on 85 ℃.In medicine liquid droplet to the 8 ℃ liquid paraffin, take out drop pill, oil removing, screen cloth selects ball, promptly.The result shows, prepared drop pill rounding, even, consistent, the no adhesion phenomenon of color and luster of size.By measuring under Chinese Pharmacopoeia version in 2000 the method disintegration item, the result does not add the average 2.44min of baffle plate by screen cloth, meets the pharmacopeia regulation this disintegration.
Embodiment 29
Crude drug Radix Salviae Miltiorrhizae 26.0g, Radix Notoginseng 25.5g, Fructus Aurantii 25.5g; Adjuvant sucrose ester 15.0g.
With 80% ethanol extraction Radix Salviae Miltiorrhizae, Fructus Aurantii and Radix Notoginseng, obtain Radix Salviae Miltiorrhizae and Radix Notoginseng ethanol extract, get supernatant with dividing behind this extracting solution high speed centrifugation.With this liquid molecular cut off is that 50000 sulfonated polysulfone membrane carries out ultrafiltration, and ultrafiltrate concentrates and obtains the extractum that relative density is 1.35～1.39 (55 ℃).The operating condition of ultrafiltration technology is: the inlet pressure of ultrafiltration is 0.5Mpa, and the liquid outlet pressure ratio inlet pressure of ultrafiltration hangs down 0.25kPa.The ultrafiltration initial stage is adopted lower pressure, slowly boosts then; In ultra-filtration process, adopt the periodic pressure fluctuation, the pressure wave moment is 0.2Mpa.The feed liquid flow velocity is 4.0m/s, in the ultra-filtration process, adopts periodically flow fluctuation so that produce pulsating flow or non-stationary flow in membrane channels, the flow speed wave moment is 2.0m/s, feeds nitrogen in the ultrafiltration system discontinuous, forms the gas-liquid stream of pulses, cycle is that 2h ventilates once each 1 minute.Feed temperature is 50 ℃, when feed liquid stock solution is concentrated 1/5, adds the water ultrafiltration again 2 times, and the pH value of feed liquid is controlled at 9.
Get that above-mentioned extractum and adjuvant sucrose ester and polyoxyethylene monostearate are mixed evenly to be heated to 60 ℃ of temperature, change material after 30 minutes, move in the dropping-pill machine jar that jar temperature remains on 90 ℃.In medicine liquid droplet to the 5 ℃ liquid paraffin, take out drop pill, oil removing, screen cloth selects ball, promptly.The result shows, prepared drop pill rounding, even, consistent, the no adhesion phenomenon of color and luster of size.By measuring under Chinese Pharmacopoeia version in 2000 the method disintegration item, the result does not add the average 2.64min of baffle plate by screen cloth, meets the pharmacopeia regulation this disintegration.
Embodiment 30
Crude drug Radix Salviae Miltiorrhizae 49.0g, Radix Notoginseng 12.0g, Fructus Aurantii 17.0g, Styrax 0.27g; Adjuvant sucrose ester 11.0g, polyoxyethylene monostearate 12.0g.
Radix Salviae Miltiorrhizae, Fructus Aurantii and the pseudo-ginseng of coarse pulverization to extraction pot, added 5 times of water gagings, decocted 2 hours, filter, filtering residue carries out second time and extracts, and adds 4 times of water gagings, fried in shallow oil 1 hour, and filtration, filtering residue discards, merging filtrate.Filtrate is that 60000 poly (ether sulfone) film carries out ultrafiltration with molecular cut off, and ultrafiltrate concentrates and obtains the extractum that relative density is 1.35～1.39 (55 ℃).The operating condition of ultrafiltration technology is: the inlet pressure of ultrafiltration is 0.35Mpa, and the liquid outlet pressure ratio inlet pressure of ultrafiltration hangs down 0.20kPa.The ultrafiltration initial stage is adopted lower pressure, slowly boosts then; In ultra-filtration process, adopt the periodic pressure fluctuation, the pressure wave moment is 0.2Mpa.The feed liquid flow velocity is 3.0m/s, in the ultra-filtration process, adopts periodically flow fluctuation so that produce pulsating flow or non-stationary flow in membrane channels, the flow speed wave moment is 2.0m/s, feeds nitrogen in the ultrafiltration system discontinuous, forms the gas-liquid stream of pulses, cycle is that 2h ventilates once each 1 minute.Feed temperature is 40 ℃, when feed liquid stock solution is concentrated 1/8, adds the water ultrafiltration again 2 times, and the pH value of feed liquid is controlled at 7.5.
Get above-mentioned extractum and Styrax, evenly mixed with adjuvant sucrose ester and glyceryl monostearate, be heated to 60 ℃ of temperature, change material after 30 minutes, move in the dropping-pill machine jar that jar temperature remains on 90 ℃.In medicine liquid droplet to the 6 ℃ liquid paraffin, take out drop pill, oil removing, screen cloth selects ball, promptly.The result shows, prepared drop pill rounding, even, consistent, the no adhesion phenomenon of color and luster of size.By measuring under Chinese Pharmacopoeia version in 2000 the method disintegration item, the result does not add the average 2.67min of baffle plate by screen cloth, meets the pharmacopeia regulation this disintegration.
Claims (10)
1. a Chinese medicine composition for the treatment of angina pectoris is characterized in that, it mainly is prepared from by following raw materials in weight portion medicine: Radix Salviae Miltiorrhizae 20～97, Radix Notoginseng 2～79, Fructus Aurantii 3～35.
2. Chinese medicine composition as claimed in claim 1 is characterized in that, described crude drug also has the Radix Angelicae Sinensis or the Herba Leonuri of 5～25 weight portions;
The Radix Astragali or Radix Ginseng or the Radix Codonopsis that perhaps also have 10～40 weight portions.
3. as the arbitrary described Chinese medicine composition of claim 1～2, it is characterized in that described crude drug also has Borneolum Syntheticum or Lignum Dalbergiae Odoriferae oil or Styrax or the Moschus or the muscone of 0.2～3 weight portion.
4. as the arbitrary described Chinese medicine composition of claim 1～3, it is characterized in that it is prepared from by the preparation method that comprises the steps:
(a) with Radix Salviae Miltiorrhizae, Radix Notoginseng, Fructus Aurantii, perhaps Radix Salviae Miltiorrhizae, Radix Notoginseng, Fructus Aurantii, Radix Angelicae Sinensis or Herba Leonuri, perhaps Radix Salviae Miltiorrhizae, Radix Notoginseng, Fructus Aurantii, the Radix Astragali or Radix Ginseng or Radix Codonopsis are separately or be mixed and made into water extract or alcohol extract;
(b) described extracting solution being carried out predefecation handles;
(c) further described extracting solution is carried out hyperfiltration treatment;
(d) ultrafiltrate is condensed into extractum, or adds Borneolum Syntheticum or Lignum Dalbergiae Odoriferae oil or Styrax or Moschus or muscone again, promptly.
5. Chinese medicine composition as claimed in claim 4 is characterized in that, described alcohol extract is to be selected from the following lower alcohol or the extracting solution of its mixture: methanol, ethanol, normal propyl alcohol, isopropyl alcohol, n-butyl alcohol, isobutanol; And/or;
Described predefecation is treated to coarse filtration-adsorption clarification, adsorption clarification-high speed centrifugation, coarse filtration-microfiltration or coarse filtration-precipitate with ethanol; And/or;
The used ultrafilter membrane of described hyperfiltration treatment is selected from: cellulose diacetate film, three cellulose acetate membrane, cyanoethyl cellulose film, polysulfone membrane, sulfonated polysulfone membrane, poly (ether sulfone) film, sulfonated polyether sulfone film, polysulfonamides film, phenolphthalein side group polyarylsulfone (PAS) film, polyvinylidene fluoride film, polyacrylonitrile film, polyimide film, cellulose membrane, methyl methacrylate-acrylonitrile copolymer film, polyacrylonitrile/cellulose diacetate blend film, the dynamically ultrafilter membrane that forms, and the Modified Membrane of above-mentioned film; The molecular cut off of its ultrafilter membrane is 6000～80000; And/or;
The operating procedure condition of described hyperfiltration treatment is as follows: the inlet pressure of ultrafiltration is 0.1～0.5MPa, and the liquid outlet pressure ratio inlet pressure of ultrafiltration hangs down 0.25～0.5kPa; Feed temperature is 15～50 ℃; The pH value of feed liquid is controlled at 5～9; When feed liquid stock solution is concentrated 1/15～1/5, add water or dilute alcohol solution ultrafiltration 1～2 time again; And/or;
In the process of described ultrafiltration separately or unite the following method that adopts: periodic pressure fluctuation, periodically flow fluctuation, feed noble gas off and on; Wherein the pressure wave moment of periodic pressure fluctuation is 0.1～0.2Mpa, and periodically the flow speed wave moment of flow fluctuation is 1.0～2.0 meter per seconds, feeds noble gas off and on and be ventilation in 0.5 hour～2 hours once, each 1 minute.
6. Chinese medicinal composition preparation for the treatment of angina pectoris, said preparation is gone up acceptable auxiliary by the arbitrary described Chinese medicine composition of claim 1～5 and any or various medicaments and is made.
7. Chinese medicinal composition preparation as claimed in claim 6, it is characterized in that said preparation is a drop pill, this drop pill is to be prepared from by any Chinese medicine composition of claim 1-5 and substrate adjuvant, perhaps be prepared from by any Chinese medicine composition of claim 1-5 and substrate adjuvant and plasticity adjuvant, wherein said substrate adjuvant is selected from least a in pharmaceutically useful monosaccharide, oligosaccharide, polysaccharide, sugar ester, sugar alcohol, fruit acid, advanced higher fatty acid derivative, high fatty alcohol, polyhydric alcohol, carbamide, the polyethylene oxide derivant;
Described plasticity substrate adjuvant is selected from starch and derivant, arabic gum, dextran, chitin, sesbania gum, carrageenan, Ficus elastica, Furcellaran, tragakanta, carrageenin, tamarind gum, pectin, xanthan gum, alginic acid and salt thereof, dextrin, cyclodextrin, agar, lactose; Polyvinylpyrrolidone, crospolyvinylpyrrolidone, carbomer, polyvinyl alcohol, acrylic resin, poloxamer, silicon dioxide, gelatin, glyceryl monostearate, polyoxyethylene monostearate.
8. Chinese medicinal composition preparation as claimed in claim 7, it is characterized in that described adjuvant is lactose and starch, xylitol and arabic gum, sucrose ester and glyceryl monostearate, sucrose ester and polyoxyethylene monostearate, sucrose ester, polyoxyethylene monostearate and cross-linking sodium carboxymethyl cellulose, a kind of combination in sucrose ester, polyoxyethylene monostearate, cross-linking sodium carboxymethyl cellulose and the silicon dioxide.
9. Chinese medicinal composition preparation as claimed in claim 8, it is characterized in that described adjuvant is lactose and starch, xylitol and arabic gum, sucrose ester and glyceryl monostearate, sucrose ester and polyoxyethylene monostearate, sucrose ester, polyoxyethylene monostearate and cross-linking sodium carboxymethyl cellulose, a kind of combination in sucrose ester, polyoxyethylene monostearate, cross-linking sodium carboxymethyl cellulose and the silicon dioxide.
10. Chinese medicinal composition preparation as claimed in claim 9 is characterized in that the described substrate adjuvant and the ratio of the weight of medicine are 1: 0.1～1; And/or;
The weight ratio of described substrate adjuvant and plasticity composition is 1: 0～1.5.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610014202 CN101085081A (en) | 2006-06-08 | 2006-06-08 | Composition containing fructus aurantii for treating cardiovascular diseases and its preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610014202 CN101085081A (en) | 2006-06-08 | 2006-06-08 | Composition containing fructus aurantii for treating cardiovascular diseases and its preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101085081A true CN101085081A (en) | 2007-12-12 |
Family
ID=38936366
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200610014202 Pending CN101085081A (en) | 2006-06-08 | 2006-06-08 | Composition containing fructus aurantii for treating cardiovascular diseases and its preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101085081A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102846899A (en) * | 2012-09-13 | 2013-01-02 | 李承平 | Storax tablet combination |
| CN110272508A (en) * | 2019-07-23 | 2019-09-24 | 广东药科大学 | A kind of preparation method and its usage of Fructus Aurantii polyoses extract |
| CN113262262A (en) * | 2021-07-07 | 2021-08-17 | 天津中医药大学第一附属医院 | Traditional Chinese medicine preparation for treating phlegm-heat stasis type stable coronary heart disease and preparation method thereof |
-
2006
- 2006-06-08 CN CN 200610014202 patent/CN101085081A/en active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102846899A (en) * | 2012-09-13 | 2013-01-02 | 李承平 | Storax tablet combination |
| CN110272508A (en) * | 2019-07-23 | 2019-09-24 | 广东药科大学 | A kind of preparation method and its usage of Fructus Aurantii polyoses extract |
| CN110272508B (en) * | 2019-07-23 | 2021-03-16 | 广东药科大学 | Preparation method and application of fructus aurantii polysaccharide extract |
| CN113262262A (en) * | 2021-07-07 | 2021-08-17 | 天津中医药大学第一附属医院 | Traditional Chinese medicine preparation for treating phlegm-heat stasis type stable coronary heart disease and preparation method thereof |
| CN113262262B (en) * | 2021-07-07 | 2022-11-08 | 天津中医药大学第一附属医院 | Traditional Chinese medicine preparation for treating phlegm-heat stasis type stable coronary heart disease and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101085071B (en) | Traditional Chinese medicinal composition containing red sage root and haw and its preparation | |
| CN101085012B (en) | Composition containing safflower for treating cardiovascular diseases and its preparation | |
| CN101085024A (en) | Traditional Chinese medicinal composition containing red sage root and ginkgo leaves and its preparation | |
| CN101084986B (en) | Traditional Chinese medicinal composition containing notoginseng and kudzuvine root and its preparation | |
| CN101085006A (en) | Composition containing kudzuvine root for treating cardiovascular diseases and its preparation | |
| CN101085047A (en) | Composition containing fleece flower root for treating cardiovascular diseases and its preparation | |
| CN101085064B (en) | Composition containing radix paeoniae rubrathe for treating cardiovascular diseases and its preparation | |
| CN101085027B (en) | Traditional Chinese medicinal composition containing red sage root and kudzuvine root and its preparation | |
| CN101085008A (en) | Composition containing acanthopanax root for treating cardiovascular diseases and its preparation | |
| CN101085134A (en) | Composition containing dragon blood for treating cardiovascular diseases and preparation | |
| CN101085004A (en) | Traditional Chinese medicinal composition containing red sage root, ligusticum wallichii and borneol or storax and its preparation | |
| CN101085070B (en) | Traditional Chinese medicinal composition containing notoginseng and haw and its preparation | |
| CN101084996B (en) | Traditional Chinese medicine containing red sage root and its preparation | |
| CN101085081A (en) | Composition containing fructus aurantii for treating cardiovascular diseases and its preparation | |
| CN101085011A (en) | Composition containing corydalis tuber for treating cardiovascular diseases and its preparation | |
| CN101085010A (en) | Composition containing rhus chinensis for treating cardiovascular diseases and its preparation | |
| CN101084957A (en) | Composition containing notoginseng and rhus taishanensis for treating cardiovascular diseases and preparation thereof | |
| CN101085007B (en) | Composition containing erigeron breviscapus for treating cardiovascular diseases and its preparation | |
| CN101084958B (en) | Composition containing notoginseng and acanthopanax root for treating cardiovascular diseases and preparation thereof | |
| CN101085009A (en) | Composition containing barrenwort for treating cardiovascular diseases and its preparation | |
| CN101085136B (en) | Traditional Chinese medicine composition containing red sage root and cyperus rotundus and its preparation | |
| CN101085057B (en) | Traditional Chinese medicinal composition containing red sage root, and radix paeoniae rubrathe and its preparation | |
| CN101084960B (en) | Traditional Chinese medicinal composition containing notoginseng and its preparation | |
| CN101085013A (en) | Traditional Chinese medicinal composition containing red sage root, safflower, radix astragali and dalbergia oil and its preparation | |
| CN101085145B (en) | Traditional Chinese medicine composition containing red sage root, dioscorea panthaica or huangyangning and its preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20071212 |